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ABSTRACT OF DISSERTATION

Investigation of Multidrug Efflux Transporter AcrB in Escherichia coli: Assembly,
Degradation and Dynamics
The Resistant Nodulation Division (RND) super family member, tripartite AcrAAcrB-TolC efflux pump, is a major contributor in conferring multidrug-resistance in
Escherichia coli. The structure of the pump complex, and drug translocation by functional
rotation mechanism have been widely studied. Despite of all these data, the dynamics of
the assembly process of the pump and AcrB during functional rotation in the process of
drug efflux remains poorly understood. My thesis focuses on understanding the pump
assembly process, dynamics of AcrB in functional rotation mechanism, and also investigate
the mechanism of degradation of AcrB facilitated by a C-terminal ssrA tag.
In the first project, I studied the impact of relative flexibility at the inter-subunit
interface utilizing disulfide bond crosslinking, minimum inhibitory concentration (MIC),
and EtBr efflux assay. Six inter-subunit disulfide links were inserted into the periplasmic
domain of AcrB using site-directed mutagenesis. Based on results from MIC measurement,
the double Cys mutants tested led to equal or higher susceptibility to AcrB substrates
compared to their corresponding single mutants. EtBr accumulation assays was conducted
utilizing Dithiothreitol (DTT) as the reducing agent. In two cases, the activities of the
double Cys-mutants were partially restored by DTT reduction, indicating the importance
of relative inter-subunit movement in the respective location for function. In addition,
crosslinking at the other 4 sites did not have such an effect.
In the second project, I tested the effect of over-expressing functionally defective
pump components in wild-type E. coli cells to probe the pump assembly process. The
incorporation of defective components is expected to reduce the complex's efflux
efficiency and lead to the so-called “dominant negative” effect. The study examined two
groups of mutants defective in different aspects and found that none of them demonstrated
the expected dominant-negative effect, even at concentrations many folds higher than their
genomic counterpart. Based on the data, the assembly of the AcrAB-TolC complex appears
to have a proof-read mechanism that effectively eliminated the formation of the futile pump
complex.

Moreover, I utilized a novel tool- transposons library creation in studying the possible other
proteases that contribute to the degradation of the AcrB-ssrA. Using the next-generation
sequencing, I identified the already known clpX gene, and MIC and western blot analysis
confirmed the results. While this result demonstrated the effectiveness of the strategy, the
current library size is too small and does not yield novel genes related to AcrB-ssrA
degradation.
KEYWORDS: multidrug efflux pump, AcrB, assembly, disulfide, conformational
changes, ssrA
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CHAPTER 1. Introduction
1.1

Discovery and history of Antibiotics
Human life expectancy during the middle ages was low, and one main reason for

this was infectious diseases. During this time, infectious diseases were one of the primary
causes of mortality, and bacterial infections were among the common causes of these
infectious diseases1. Tuberculosis, bubonic plague, anthrax, and cholera, for example,
were all widespread infections2. However, with the discovery of antibiotics, this all
changed. Mycophenolic acid isolation by Bartolomeo Gosio in 1893 was regarded as the
first pure isolation of an antibiotic agent3. Following this initial impetus, the enormous
efforts from scientists worldwide led to the discovery of a vast array of antimicrobial
agents, which has been a great boon in improving human life expectancy and the quality
of life.
Antibiotic is derived from an antonym to symbiosis: "antibiose." Selman Waksma
first used the term "antibiotic" in 19423, 4. In 1890, Paul Vuillemin used this word to
describe the relationships between different microbes such as bacteria vs. protozoa, fungi,
and bacteria. Antibiotics or antibacterials are natural secondary metabolites produced by
bacteria and fungi, consisting of inhibitory or lethal/killing properties against bacteria.
Natural anti-fungal, anti-viral, and antibacterial substances have been used as
remedies for a long time5. For example, in Jordan, red soils are utilized as antibiotics, and
several herbals are exploited in traditional Chinese medicine as antimicrobial agents.
Qinghaosu (artemisinin), a traditional Chinese medicinal, was later revealed to be a potent
anti-malarial drug. This was isolated from Artemisia plants in the 1970s 6
The emergence of the organic synthesis of antibiotics in the 19th century ushered
in the discovery of numerous antibacterial drugs. The first man-made antibacterial agent
was arsphenamine synthesized by Alfred Bertheim, which was approved as a drug in 1910.
Later, in 1928, Alexander Fleming observed a Staphylococcus aureus plate had been
contaminated with the fungus Penicillium notatum, (now P. chrysogenum). He observed
an intriguing pattern on the plate. Closer to the fungus, the bacteria were not growing,
marked by clear areas on the plate7. The extract from P. notatum was later named penicillin
in 1929 and has been used to treat infection by several pathogenic bacterial strains, mainly
1

Gram-positive ones, ever since7. In 1940, commercial production of penicillin began and
was used to treat soldiers injured in World War II. The X-ray crystallographic structure of
penicillin was analyzed by Dorothy et al., who categorized it as the first member of the βlactam family8.
The discovery of penicillin ushered in a new era of antibiotics. With the
development of techniques and accessibility, scientists developed various antibiotics by
adding different functional groups. The timeline of antibiotic development is shown in
Figure 1.1. The period between 1940 to 1960 is considered the golden era of antibiotics
development. Over 100 novel antibiotics have been introduced to the market during this
period due to the rapid identification and characterization of compounds with antibacterial
activities. The subsequent significant antibiotic discovery was the sulfonamide groups.
After that, another milestone was achieved in 1943 by the discovery of the aminoglycoside
antibiotics streptomycin. This antibiotic group exhibited activity against both Grampositive and Gram-negative strains. The majority of these antibiotics were produced
through fermentation methods except chloramphenicol which was synthesized.

Figure 1.1 The timeline of antibiotic discovery and development of antibiotic resistance5.
Copyright © 2010, American Society for Microbiology.
Based on the mechanism of action, antibiotics can be divided into two major
groups. i) bacteriostatic; these inhibit bacterial growth by interrupting the major cellular
processes such as DNA replication, protein biosynthesis, and cellular metabolism (e.g.,
tetracycline, sulfonamides).
2

ii) bactericidal- these antibiotics kill bacteria by disturbing cell membrane
permeability, disrupting cell wall synthesis, and essential bacterial enzymes (e.g.,
penicillin, cephalosporin). The major groups of antibiotics and their mechanism of action
are summarized in Table 1.

1.2

Antimicrobial resistance, the current development, and challenges
Scientific knowledge and technology have immensely contributed to the fight

against microbes and benefited human and animal health. The use of antimicrobial drugs
has been one of the most successful therapies in human and veterinary medicine9. Even
though antibiotics are powerful in treatments, they lose their efficiency over time. This loss
leads to the survival of a subpopulation of bacteria that evolve to be resistant to the drugs.
Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi, and parasites
change over time and no longer respond to the antimicrobial drugs. The overuse of
antimicrobial agents in healthcare and veterinary, agriculture, and the poorly regulated
antibiotic market has significantly contributed to developing resistant strains against
antibiotics10-12
The first antibiotic-resistant strain was found soon after the discovery of penicillin.
A Staphylococcus strain was found to be resistant to penicillin, and as an alternative,
methicillin was developed13. Later, with the increase of antibiotic usage, more resistant
strains emerged.
At present, AMR is one of the major threats to global health. The continuous
evolvement of pathogenic microbes against the developed and available drugs is menacing
humanity by causing deadly infections14-16. The efforts by the scientific community to
characterize and develop new antibiotics had helped us reduce the impact of resistant
strains temporarily. However, as new strains of resistant bacteria emerge, the battle proves
to be a difficult one17. Currently, there are resistant bacteria to all the available antibiotics,
causing a huge problem in treating bacterial infections. According to the Centers for
Disease Control and Prevention (CDC) and World Health Organization (WHO), about 2.8

3

million people are infected with antibiotic-resistant bacteria or fungi. As a result, more than
35,000 people lose their lives each year in the United States15, 16.
Bacteria develop resistance to antibiotics through a variety of mechanisms.
Horizontal gene transfer during cell divisions, overexpression of specific genes, decreased
membrane permeability and increased efflux, antibiotic inactivation, modification of the
drug target site, and creation of by-pass reactions to prevent inhibitory effects are a few
such mechanisms 18. Among the drug-resistant bacteria, more problematic ones are placed
in a group called ESKAPE, named as an acronym for six bacteria; Enterococci,
Staphylococcus aureus, Klebsiella pneumoniae Acinetobacter baumannii, Pseudomonas
aeruginosa, Enterobacter spp.
There are several approaches that we can consider in fighting against the pathogenic
bacteria, i) Reduction in the spread of bacterial pathogens through the maintenance of
personal hygiene and public health awareness ii) Development of new antibiotics as well
as novel anti-virulence strategies to slow down bacterial evolution and resistance iii) Proper
regulation of the antibiotics use17. Apart from reducing the spread of resistant strains, there
is a huge requirement to develop new antibiotics. However, the period after the 1960s is
called the lean years in antibiotic development. This is because the number of new
antibacterial drugs developed and approved is rapidly declining. Since then, only four new
classes of antibiotics have been approved and are available commercially19. Most recently,
in 2015, teixobactin was developed and approved as a new antibiotic. Teixobactin acts by
inhibiting bacterial cell wall synthesis and exhibited a high efficiency against Grampositive bacteria20.
Breakthroughs in genomics and proteomics have brought new possibilities to
antimicrobial research21-23. The first complete bacterial genome sequence became available
in 199524, 25. However, even with such developments, the development of new antibiotics
has lagged far behind. Antimicrobial drug discovery is a complex process mainly due to
the inefficient penetration of compounds into bacterial cells26. Moreover, other major
problems associated with developing new antibiotics are i) traditional and nontraditional
methods have already identified the low hanging fruits of the antibiotics ii) it takes about
8-12 years from the discovery of an antibiotic to the point of commercial availability. iii)
4

drugs need to be safe and effective, optimization process needs to consider the suitability
of its use in near future iv) cost of production is high19.
From an industrial perspective, most of the early companies have stopped or
significantly downsized their focus on antimicrobial drug research27. In the progress of
commercial drug development, industrial research focuses on identifying broad-spectrum
drug targets and novel inhibitors, determining the molecular mode of actions, and
developing combination drug therapy modes28. However, there are resistance mechanisms
against these commercial antibiotics, which raises the need to establish new inhibitors29.
For example, studies are being conducted to produce novel inhibitors for the β-lactam
antibiotics, which are considered the most produced and used antibiotics30.
For acceleration of antibiotic production, in 2016, Combating Antibiotic-Resistant
Bacteria Biopharmaceutical Accelerator (CARB-X) was launched by USA31. It is a nonprofit partnership dedicated to the rapid innovation of antibacterial agents and other
products to combat drug-resistant bacteria. It is the world's most prominent early
development pipeline of antibiotics.
Even with the development of new drugs, there is always the possibility that
bacteria will eventually develop resistance against them. Hence, regulation of antibiotic
use is eassential6. For example, the European Union (EU) recommends the cautious use of
antimicrobial agents in medicine32. They have regulations in monitoring the sales and usage
of antibiotics and assessing the risk of developing drug resistance by using antibiotics on
animals.
1.3

Multidrug resistance in bacteria (MDR)
Some bacteria become resistant to a broad range of antibiotics, creating multidrug-

resistant bacteria (MDR)/"superbugs." Drug resistance to all the major antibacterial classes
in Gram-negative and Gram-positive bacteria is prevalent 33. Multidrug-resistant bacteria
are more concerning due to their impact on available effective therapies against bacterial
infections34. An estimated seven million deaths occur due to infections by MDR bacteria
worldwide each year, and this number could increase to 10 million by 205015, 16.

5

As mentioned above, multidrug-resistant bacteria have become one of the major
global problems by hindering the ability to cure infectious diseases using currently
available antibiotics35. For example, in 1991, an MDR strain of M. tuberculosis was
isolated in the USA, which was resistant to isoniazid, rifampin, ethambutol, streptomycin,
kanamycin, ethionamide, and rifabutin. Due to this extreme situation, a new antibiotic,
Bedaquiline received fast-track FDA approval to treat MDR tuberculosis. According to the
reports by the CDC, bacterial strains have developed resistance against "last resort"
antibiotics such as carbapenems and colistin 36. Hence, the requirement for designing drugs
against MDR is crucial at present. Glycopeptides, quinolones, oxazolidinones, and
antibacterial cationic peptides are being studied to see if they can be improved to be more
effective against MDR bacteria. 37, 38.
Drug-resistant bacteria develop resistance mechanisms due to selective pressure,
and the acquired genetic alterations pass from generation to generation, creating a whole
population of resistant bacteria. There are several mechanisms from which microbes
develop drug resistance, i) genetic mutation or enzymatic alteration, e.g., production of
MRSA by the acquisition of mecA gene ii)inactivation of drugs by enzymatic degradation,
e.g., production of β-lactamase that hydrolyze the β-lactams antibiotics iii)antibiotic
modification, e.g., aminoglycosides iv) Loss of porin and changes in membrane
permeability, e.g., polymyxin resistance v)alteration of the drug target site, e.g., quinolones
vi) overexpression of specific group proteins such as multidrug efflux pumps, e.g.,
tetracycline resistance (Figure 1.2)39, 40. Different classes of antibiotics have different
mechanisms of drug resistance depending on their mechanism of action. These are
summarized in Table 1.1

6

Figure 1.2 The figure illustrates different mechanisms bacteria use to acquire drug
resistance. The figure belongs to 39.
The overexpression of efflux pumps is the most prevalent multidrug resistance
mechanism, while other mechanisms lean towards single drug resistance. Efflux pumps
expel out a broad range of molecules, including antibiotics, dye, detergents, and salt in
Gram-negative and Gram-positive bacteria.18, 41 Overexpression of efflux pumps reduces
the concentration of the drug within the bacterial system by exporting it into the external
environment, thereby contributing to intrinsic resistance42.
Table 1.1 Class of antibiotics, mode of action, and resistance mechanisms.
Class of Antibiotics/

5, 6, 9, 29

Mechanism of action

Drug resistance mechanism

β-lactam (1929)

Inhibition of bacterial

Production of the β lactamase

Penicillin, Methicillin,

cell wall synthesis.

Alteration of the penicillin-

Year of first
introduction/examples

Carbapenems

binding protein (PBP)

Sulfonamides (1935)

Inhibition of folate

Enhanced efflux and alteration

Sulfadiazine

synthesis

of targets
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Table 1.1 (Continued)
Polypeptides (1939)

Disruption of the Gram-

Bacitracin, Colistin

negative bacterial outer

Genetic mutations

membrane and
membrane permeability
by associating with
anionic
lipopolysaccharides
Aminoglycosides

Inhibition of protein

Phosphorylation, acetylation,

(1943)

synthesis and disruption

nucleotidylation, efflux ,and

Gentamicin, Kanamycin,

of the bacterial cell

target modification

Tobramycin, Neomycin,

membrane

Spectinomycin
Tetracyclines (1945)

Inhibition of protein

Overexpression of efflux

Tetracycline,

synthesis

mechanism. Synthesis of

Doxycycline,

alternative elongation factor to

Tigecycline

prevent ribosomal binding
enzymatic degradation of
tetracycline

Lipopeptides (1947)

Disruption of the

Daptomycin, Polymixin

bacterial membrane,

B

inhibition of protein,

Alteration of drug target

DNA, and RNA
synthesis
Chloramphenicol (1948)

Inhibition of protein

Enzymatic inactivation by

synthesis by binding to

acetylation, via different types

the ribosome

of chloramphenicol
acetyltransferases, target
mutations, and efflux of
chloramphenicol,
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Table 1.1 (Continued)
Macrolides (1950)

Inhibition protein

Modifications in target

Erythromycin,

synthesis

Enhanced efflux

Oxazolidonones (1952)

Inhibition of protein

Enhanced efflux and alteration

Linezolid, Torezolid

synthesis

of targets

Glycopeptides (1953)

Inhibition of

Target alteration by genetic

Vancomycin,

peptidoglycan synthesis

mutations (vanA, vanB)

Teicoplanin

in bacterial cell wall

Reprogramming peptidoglycan

Clarithromycin,
Azithromycin

biosynthesis
Quinolones (1962)

Inhibition of DNA

Target modification,

Ciprofloxacin, Ofloxacin

replication and

acetylation, and efflux

transcription.

Lincosamides (1963)

Inhibition of protein

Nucleotidylation, efflux, altered

Lincomycin,

synthesis

target

Clindamycin

1.4

Multidrug resistance mechanisms
Among the severe bacterial infections, the majority of them are related to the MDR

Gram-negative bacterial species43. Gram-negative bacteria have three main layers in their
cell walls: the outer membrane, inner membrane, and peptidoglycan cell wall. Grampositive bacteria have two principal layers: the peptidoglycan cell wall and the inner
membrane. These multi-layers provide an extra barrier for the drugs and other influx
compounds. One of the multidrug resistance mechanisms in Gram-negative bacteria is
efflux pumps. Most of these are located in the inner membrane. These pumps transport
substrates from the inner membrane and periplasm through an outward channel. The
9

detailed analysis of these pumps in Gram-negative and Gram-positive bacteria has revealed
they have versatile, functional roles in regulating compounds during infections, cell-to-cell
communications, and the formation of biofilms44.
Based on the sequence, structural, and functional analysis, efflux pumps are
categorized into five major superfamilies. These are known as Resistance nodulation
division (RND), Small molecule resistance (SMR), ATP binding cassette (ABC),
Multidrug and toxic compound extrusion (MATE), and Major facilitator superfamily
(MFS)45, 46 (Figure 1.3). Among these, ABC superfamily uses ATP as the energy source
while other families use electrochemical gradient47. ATP- dependent ABC family is
diverse in importing or exporting solutes and functions as modulators of ion channels. An
example of an ABC transporter is MacAB-TolC.48
The MFS group is considered the largest and most diverse family of transporters.
Moreover, it is known as the uniporter-symporter-antiporter superfamily; uniporters (
move substrates across the lipid bilayer without any coupling ions); symporters (substrate
transport is coupled with ion and transport in the same direction) and antiporters (ion and
substrates

are

moved

in

opposite

directions).

E.g.,

glycerol

3-

phosphate/phosphate exchanger GlpT belongs to the MFS group. Most of this superfamily
functions as single, monomeric units. SMR family proteins are small transporters that show
resistance against quaternary ammonium compounds and other lipophilic cations such as
EmrE in E.coli. MATE family transporters utilize proton or sodium gradient to efflux
substrates from the bacteria.44
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Figure 1.3 Different superfamilies of efflux pumps are represented in Gram-negative
bacterial membrane.
Resistance nodulation division (RND), small molecule resistance (SMR), ATP binding
cassette (ABC), Multidrug and toxic compound extrusion (MATE) and Major facilitator
superfamily (MFS).44 Reprinted with permission from Macmillan Publishers Ltd., Springer
Nature.
1.4.1 AcrAB-TolC efflux pump system in E. coli
One of the most studied members of the resistance nodulation division (RND)
family is the AcrAB-TolC (Acriflavin binding A and B- Tolerance Colecin) efflux system
in Gram-negative bacteria49,

50

(Figure 1.4). AcrA-AcrB-TolC efflux pump confers

resistance to a broad range of antimicrobial compounds such as β-lactams, tetracycline,
novobiocin, fluoroquinolones, and fusidic acids51,

52

. The study into the efflux pump

structure has evolved over the years through the work of many research groups. Mainly, it
is a proton antiporter and has three distinct protein groups. This tripartite assembly consists
of an outer membrane protein TolC, a plasma membrane-spanning protein that acts as the
transporter -AcrB, and a periplasmic membrane fusion protein AcrA that connects the two
trans-membrane components. The role of these has been debated over the years. The most
recent finding summarizes that AcrB, the inner membrane-spanning trimer, acts as a drug
11

recognition transporter. AcrA, which is in the periplasm, supports the formation of the
pump by anchoring AcrB and TolC. TolC is the outer membrane channel from where the
drug is transported out of the cell. The recent crystal structure of the efflux pump supports
the functional rotating mechanism of drug binding and extrusion of the pump53-55.
Upon recognition of substrate, AcrB uses the energy from the proton-motive force
derived from substrate/proton antiport. Substrates are recruited from the periplasmic space
and outer leaflet of the inner membrane56, 57. In the periplasm, AcrA serves as a bridge
between the inner and outer membranes to transfer the substrate to TolC in the outer
membrane.

58, 59

. TolC, shared by many other efflux systems, exports the drug into the

extracellular environment60, 61 The individual crystal structures of AcrA, AcrB, and TolC
have been solved62-64. The near-atomic resolution cryo-EM structure of the entire AcrABTolC complex solved by Wang et al.; reveals the intricate interacting interfaces between
components of the pump65. The compositional stoichiometry of the complex was
postulated to be AcrB: AcrA: TolC interaction in a 3:6:3 ratio to facilitate the transport of
molecules across the double-membrane bacterial cell66-68.

Figure 1.4 Structure of asymmetric AcrABZ-TolC pump visualized inside view.
OM-outer membrane, IM-inner membrane. The text color represents the respective section
of the pump. E.g.: AcrB-Blue65. Reprinted with permission from Elife Sites.
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1.4.2 The deep interpenetration and the Tip-to-tip Models of the AcrAB-TolC Efflux
Assembly
AcrA -AcrB-TolC is a tripartite protein complex theworking together to transport
substrate through the periplasm and membranes out of the bacteria system.65, 69. Initially,
by utilizing X-ray crystallography and electron microscopy and recently by novel
techniques like cryo-EM, numerous studies have been conducted to elucidate the structure
of these efflux pumps65, 70. The first interpreted model of the pump assembly was referred
to as the deep interpenetration model (Figure 1.5). This model shows that AcrB and TolC
have direct interactions with each other, with each hairpin of AcrA contacting each groove
on TolC surface, necessary to the functional rotation mechanism71. This was revealed from
74 different in vivo cysteine cross-linking studies between AcrA and AcrB.
However, another model has been recently postulated called "the tip-to-tip model."
The AcrA hairpin in a barrel-like conformation contacts TolC in a tip-to-tip arrangement,
as exemplified by Wang and coworkers in their published near-atomic resolution cryo-EM
structure of the AcrAB-TolC complex assembly.65
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Figure 1.5 The comparison of two different proposed models for the AcrAB-TolC pump
assembly.
The left side shows the deep inter-penetration model, and the rights side exhibits the tip to
tip model.72 Copyright © 2020 Marshall and Bavro, Frontiers in Molecular Biosciences.
1.4.3 Exit duct of the efflux pump- Tolerance to Colicin (TolC)
The outer membrane protein (OMP) of the AcrAB-TolC complex is TolC, which
has a primary role in the expulsion of the molecules, toxins, and drugs from the cell. Many
different biological processes share TolC in E. coli in the cell. Trimeric TolC is a 12
stranded β-barrel composed of 493AAs in each protomer. It spans through the outer
membrane and periplasmic space. TolC is 140 Å in length and has a funnel/tube shape with
a tight constriction at the periplasmic end. Once a complex recruits it for assembly, it
translocates the molecules into the external environment.73 The TolC tube is small, with a
diameter of 3.9 Å. The two major domains, the channel domain, and the tunnel domain,
are a 40 Å β-barrel and a 100 Å α-helical barrel, respectively.51 TolC consists of protomers
with structural repeats, forming a six-fold symmetry. It has three docking domains that
include a central funnel leading to the TolC lumen. It creates trimers with structural regions
such as periplasmic helical barrel, transmembrane barrel, and folds in the periplasm74, 75.
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1.4.4 Adaptor protein- Acriflavine resistance protein A (AcrA) Structure
AcrA can undergo large-scale conformational changes because of its flexibility.
AcrA comprises of four domains with flexible linkers: the α-helical hairpins, lipoyl, the βbarrel, and the proteolytically labile membrane-proximal (MP) domains.59 The other
domains interact with AcrB except for the α hairpin that docks to TolC.61,

76-78

The

functional relevance of AcrA has been revealed through mutational studies. These studies
have shown that deletion of the gene locus of AcrA led to the total abrogation of the efflux
pump activity.79, 80 AcrA or other PAPs are attached to the membrane through an acylated
cysteine residue at position 25 or via a transmembrane residue at the N terminus. This
attachment to the membrane is not relevant to the efflux function because even when the
attachment is removed, the soluble AcrA retains its activity.59
1.4.5 Acriflavine resistance protein B (AcrB) as a transporter
AcrB is a homo-trimeric protein, of which each protomer is contains 1049 amino
acids. AcrB is a very crucial protein for the effective functioning of the efflux pump. Hence,
a vast majority of the studies to find efflux pump inhibitors have focused on AcrB. The
first crystal structure of AcrB was resolved in 200263.The symmetric and asymmetric
crystal structures of AcrB protein in the apo and substrate-bound states have been
determined through various studies.53, 63, 81-85 Each subunit of the antiporter AcrB has 12
transmembrane -helices that make up the transmembrane domain (TMD) and a large
periplasmic domain (Figure 1.6).65 The TMD is necessary in proton transport and thereby
energy production through proton motive force. Two periplasmic loops reside between
TM1 and TM2 and TM7 and TM8, respectively. The periplasmic domain, which is further
divided into the porter domain and the funnel/docking domain, functions in substrate
recognition and binds to the specific drug binding pockets. Previous studies have indicated
several drug binding sites located in the AcrB (central cavity, periplasmic site), which
facilitates the broad range of recognition and binding capability of AcrB transporter.86 In
the transmembrane domain, charged residues such as Asp407, Asp 408, Lys940 are
involved in the proton translocation.
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Figure 1.6 The crystal structure of AcrB. Each protomer represents in different colors AcrB
has two major domains, a transmembrane domain and the periplasmic head domain. The
assembly of each monomer creates a jellyfish-like structure with a funnel-like opening57.
Copyright © 2015 Yamaguchi et al. Frontiers in Molecular Biosciences.
AcrB porter domain further divides into four major subdomains known as PN1,
PN2, PC1, and PC2. The N terminal subdomains PN1 and PN2 are positioned between
transmembrane helices TM1 and TM2. The C terminal subdomains PC1 and PC2 are
located between TM7 and TM8. These subdomains have been revealed to have a
significant role in the drug transport mechanism. Furthermore, PN1 and PC2, PN2, and
PC1 subdomains form a rigid β- sheet structure comprising two structural subunits called
PN1-PC2 and PN2-PC1. The funnel domain has two major subdomains, DC and DN
(Figure 1.7). 51, 87-89
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Figure 1.7 This figure shows the enlarged structure of one of the AcrB monomers A)
represent the monomer with all the subdomains and subunit structures, B) shows the
enlarge illustrations of drug binding pockets and switch loop57. Copyright © 2015
Yamaguchi et al. Frontiers in Molecular Biosciences
It was previously reported that there are two major drug-binding sites in AcrB. The
access pocket (AP) or proximal binding pocket (PBP) is a cleft formed by subdomains PC1
and PC2 at the bottom of the periplasmic domain. The deep pocket (DP)/ distal binding
pocket (DBP) located in the PN2-PC1 unit of the efflux pump is responsible for
recognizing the low molecular mass compounds. The AP and DP sites are separated by a
flexible, 11 amino acid residue known as a "switch loop," which is essential for drug
transport.87, 90 These drug binding sites have unique characteristics to facilitate different
substrate-binding, contributing to the broad range of drug specificity. It has been reported
that AP prefers larger substrates like erythromycin while DP favors smaller substrates like
minocycline.87, 91-93
The central pore is formed by associating the subdomains and is located close to
the periplasm and recognizing high molecular mass compounds (Channel (CH)1,2,3).
More recently, some studies suggest that certain substrates could gain access from the
cytoplasm through the central cavity or the transmembrane-embedded external surface of
17

the trimer.94, 95 Therefore, the AcrB has 3 major entrance pathways for drugs; i) CH1membrane surface channel entrance, ii) CH2- periplasmic entrance, and iii) CH3- central
cavity entrance. The drugs entering these 3 pathways have different characteristics,
allowing multidrug recognition by AcrB (Figure 1.8). Due to multiple entry pathways,
drug efflux from the cell is significantly efficient.46

Figure 1.8 Side and a top-down view of AcrB showing the three main intramolecular entry
channels in each monomer.Binding (blue) exit (pink) and extrusion (red)46. Reprinted
from46, Copyright (2018), with permission from Elsevier.
1.4.6

Functional Rotation mechanism of AcrB

The drug binding and extrusion mechanisms in AcrB have been highly studied.
They have continuously been modified with new findings, providing insight into how the
efflux pump causes multidrug resistance in bacteria. The AcrB transporter's structural
asymmetry shows three conformations in each protomer, reflecting a different stage of the
drug transport cycle. This was explained by the peristaltic functional rotation mechanism
(Figure 1.9)53-55, 96-99.These three different stages are termed open access (Loose-L), drug
binding (Tight-T), and drug extrusion (Open-O) cycles.53, 55, 97, 100
The AcrB has high structural homogeneity, and the protomers exhibit
characteristics protonation states in the transmembrane domain.101 According to the
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functional rotation mechanism, in the access conformation, the open and close activity of
the external cleft between the PC1 and PC2 subdomains changes the distances between the
protomers at the periplasmic domain. Substrates bind to AP/ PBP at the first stage. In the
binding conformation, the cleft opens wide, whereas in the extrusion conformation,
movement of the PC1 and PC2 subdomains causes the closure of PC2. Substrates that enter
to AP/PBP move to DP/DBP during the transition from binding to extrusion. Thereafter,
due to the movement of DBP, the substrate is expelled to the central funnel in TolC. The
proton translocation across the transmembrane domain and drug binding to the porter
domain initiate these conformational changes53. The new cryo-EM model study showed
that ligand binding is allosterically coupled with the channel-opening. The channel remains
open through the drug transport cycle, thus offering a dynamic mechanism of efflux.65

Figure 1.9 Illustration of the functionally rotating ordered multidrug binding change
mechanism mediated by AcrB82. . Reprinted from82 Copyright (2008), with permission
from Rightslink® Service and Elsevier.
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1.5

Protein degradation in bacteria
The biological networks are modulated through a series of protein expression,

function, and degradation processes. Protein degradation in cells is an important process in
regulating homeostasis and quality control of the cells. There are two major groups of
proteins; ATPases associated with various cellular activities (AAA+) proteases and
Heatshock protein70 (HSP70)102. AAA+ proteases use the energy from ATP hydrolysis to
unfold, modify, degrade, and transport proteins. These are essential for the regulations of
the proteome in cells ranging from bacteria to humans103.
The proteolytic complexes consist of proteases and peptidases. In prokaryotes, the
proteins are degraded by the ATP-dependent pathway involving proteases including
ClpAP, ClpXP, FtsH and, Lon104, 105. Two well-studied examples in prokaryotic protein
degradation are AAA+ proteases ClpAP and ClpXP. The ClpXP complex consists of two
proteins. ClpXP has a vital role in the association, unfolding, and translocation of proteins
into ClpP for degradation. The ClpX protease consists of six AAA + subunits and a ringshaped motor structure. ClpP is a 14 subunits barrel-shaped peptidase (Figure 1.10). The
six motor subunits coordinate ATP hydrolysis, and the translocation of the protein substrate
through the central pore is mediated by the conformational changes within a single subunit.
These conformational changes in one subunit subsequently drive the motions of the other
subunits106. Bacterial proteins are degraded by including a degradation peptide tag in the
coding region.
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Figure 1.10 The structures of ClpX protease and ClpP peptidase.A) Top-down view of the
ClpX protease arranges in hexameric ring. B) The side view of the ClpP arrange with 14
subunits104. . Reprinted from104 Copyright (2012), with permission from Rightslink®
Service and Elsevier.
The protein is flagged for degradation by five major peptide motifs. These are
categorized into two main types of peptides: C-terminal and N-terminal107. For instance, in
E. coli the C-terminal peptide ssrA, an 11 amino acid residue (AANDENYALAA),
facilitates the rapid degradation of soluble proteins. Furthermore, degradation signals can
be sent via the N-rule pathway through the N-terminal tagging of the protein108.
In general, the function of ssrA lies in the rescuing of stalled ribosomes (Figure
1.11). The stalled ribosome is rescued by a mechanism called trans-translation. Through
trans-translation ssrA peptide tag is added to bacterial proteins that do not have in-frame
stop codons. Trans-translation is a crucial step in preventing negative impacts on cellular
functions from the stalled ribosomes.
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Figure 1.11 The pathway of ssrA tag added to the C-terminus of incompletely synthesized
protein. Reprinted by permission from109. Copyright © 2020 Springer Applied Microbiology
and Biotechnology
Stringent starvation protein B (SspB) is a highly specific dimeric delivery/adaptor
protein that delivers ssrA- tagged proteins to ClpXP. The SspB adaptor binds to the ssrA
tag's first seven amino acids (AANDENY), anchoring it to the ClpXP protease, while ClpX
detects the last three amino acids (LAA), and unfolds the protein substrate (Figure 1.12).
110

This process enhances the degradation of ssrA-tagged proteins by ClpXP. Nyquist et al.

used different peptide tags and demonstrated that adaptor-mediated proteolysis of the
peptide-tagged protein substrates is comparatively efficient due to the increase in strength
of protease-substrate contacts.111 However, it was reported that the ssrA tagged protein
degradation in E. coli occurs even in the absence of SspB.
ClpX protease recognizes and binds to the peptide tag during the degradation
process, then unfolds the attached protein substrate, followed by translocating the
polypeptide into the proteolytic compartment ClpP, which performs the degradation of the
unfolded polypeptide into small peptide fragments (Figure 1.12).105 Chaperone rings have
a significant role in recognizing protein substrates by identifying specific tag sequences
and hydrophobic motifs of some proteins (Figure 1.13).112 The peptide-tagged protein
degradation happens through more than one protease complex (e.g., ClpAP). Hence, the
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efficient regulation of protein degradation is difficult104. In our attempt to study the lifetime
of AcrB in E. coli, we discovered that the introduction of a small peptide tag, the ssrA,
leads to the complete degradation of AcrB.113

Figure 1.12 Protein degradation by ClpXP protease.
A) Model for Adaptor-Mediated Delivery of a Tagged Substrate to a AAA+ Protease
complex B) Schematic representation of substrate recognition and degradation by AAA+
protease105. Reprinted with permission from © 2004 Cell Press. Published by Elsevier Inc.

Figure 1.13 Schematic illustration of the roles of chaperone rings in ATP-dependent
protein degradation in bacteria Protein folding chaperons, ATPases are shown in the
figure114. © 2015 Venter, Mowla, Ohene-Agyei and Ma. Frontiers in Microbiology.
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1.6

Transposons (Mobile genetic elements/"jumping genes") as a robust tool
The advent of genomics has paved the way for improved and robust phenotyping,

structural, and biochemical analytical methods. As one of the applications, molecular
genetics in bacterial phenotypic studies provides greater insight into the molecular
processes which are beneficial in medical and industrial applications. Transposons have
become one of the most versatile tools in the molecular genetic analysis of bacteria which
are widely applicable in the study, construction, and manipulation of different phenotypes
in bacteria. One of the major advantages of transposons over the traditional mutagenesis
approaches is their ability to produce mutated genes with a meager chance of multiple
insertions.
Transposons were first discovered by geneticist Barbara McClintock using the
maize genome, for which she won the Nobel Prize in 1983. Transposable elements are
generally known as "jumping genes/selfish genes".115-117 These DNA sequences move from
one place to another in the genome. Furthermore, these are capable of moving from one
genome to another, which is known as "Horizontal gene transfer" 117, 118. These events are
widely found in eukaryotes and in some of the prokaryotes as well. For instance, 90% of
the maize genome has been made up of transposons, and about 50% of the human genome
consists of Transposable Elements (TE) 118. Transposons insertion is a random process.119
It is important to understand the definition of terms that explain the transposons (Table
1.2).
Table 1.2 Definition of transposons related terms.120
Term
Transposase enzyme -(i.e.Tn5),
Transposon
Transposome
Transpositions
Transposed DNA-

Definition
Catalyzes the transposition reaction
Transposable DNA sequence containing
transposase recognition sequences
It consists of the transposon complexed
with the transposase.
The reaction, where the transposon is
inserted into the target DNA
Target DNA with a transposon insertion
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There are two major classes of transposons; i) Class I, known as retrotransposons,
uses RNA as a mediator to complete the transposition; ii) Class II are the DNA transposons
flanked by terminal inverted repeats (TIR) (Figure 1.14). Furthermore, depending on the
mode of action, they are further divided into conservative and replicative groups. In
bacteria, there are a few types of transposons: i) IS element- insertion sequence
transposons, transposase gene is flanked by inverted repeats (IR); conservative or
replicative, ii) Composite transposons; conservative (Figure 1.15), iii) Transposable
bacteriophages such as Mu phage, iv)Tn3 class transposons.

Figure 1.14 A representation of Class I and Class II transposons. The image belongs to 116
DNA transposons which are prevalent in bacteria, allow DNA rearrangement,
crucial for genomic evolution. DNA transposons have a mode of action that enables
transferring a gene from one site to another, known as the "cut and paste" mechanism.
However, these insertions mostly happen close to the parental insertions, which is called
"local hopping." The transposase encoded by the IS binds at or near the IR of DNA; the
transposition

reaction

follows

this.

In

composite

transposons

phenotype

responsible/resistance gene, DNA region is flanked by two IS elements. These IS elements
are responsible for the encoding of transposase (Figure 1.15). Our studies have used the
Tn5 transposons system, which comes under the group of composite transposons.121
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Figure 1.15 A comparison between two major types of bacterial transposons, a)IS element
and b) Composite transposons.122
1.6.1 The applications of transposons in genomic studies
The identification of transposons has led to significant discoveries in various
scientific aspects.116, 118 The main problem associated with genome studies in terms of
sequencing large DNA segments is sequencing an insert within the interior of a DNA.
Alternative techniques such as genome walking/primer walking and shotgun subcloning
have been developed to circumvent this limitation. Transposons, on the other hand, have
proven to be an effective approach.
One of the most prominent uses of transposons in bacteria is the generation of
recombinant plasmids, which helps with DNA sequencing and mapping.123 Transposon
insertions range from yeast to human DNA. These customized transposons are used as
priming sites in the sequencing process. Advantages of using transposons include: 1) it can
be designed to contain specific features, 2) assembly of a large number of transposons
insertions is easy, and 3) the unique flanking sites of transposons allows rapid identification
of insertion sites. The introduction of certain antibiotic resistance genes into bacteria (such
as E. coli, Salmonella typhimurium, and others) in vivo is another use. Similarly, the
insertion of replication origins into bacteria facilitates molecular cloning. Furthermore, in
vivo DNA transposition plays a critical part in insertional mutagenesis, which is used to
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create gene "knockouts." Integrating retroviral DNA and sequencing bacterial genomic
DNA directly from transposon insertions without cloning, as well as guiding molecular
cloning by providing genetic landmarks, are a few other examples (Figure. 1.16).124

Figure 1.16 A summary of different applications of transposons120. . The images belong to
Lucigen Inc.
1.6.2 The EZ-Tn5™ <KAN-2>Tnp Transposome™ system
The Tn5 transposons system, which has the cut and pastes mechanism, has been
widely used by researchers in different studies. Transposons library creations have
facilitated the identification of genes involved in virulence as well as non-essential
processes.125 A conjugative transposons process used in lactic acid bacteria is explained in
detail in the review by Fitzgerlad et al. 126
The EZ-Tn5™ <KAN-2>Tnp Transposome™ available through Lucigen Inc.
(Middleton, WI) is based on the stable complex interaction between the EZ-Tn5
transposase enzyme and the kanamycin-2 transposon. It provides an efficient method for
in vivo mutagenesis and target identification, allowing rescue cloning from the expected
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mutant. This system includes the antibiotic resistance gene- kanamycin. Also, the ends of
transposons are flanked by 19 bp repeats known as Mosaic Ends (ME). ME act as the EZTn5 Transposase recognition sequences (Figure 1.17).120
The transposome system is incorporated into the cells via electroporation, and once
inside, the Tn5 enzyme is activated by cytosolic Mg2+. 127, 128 This activation leads to the
random insertion of transposons into the host genome, resulting in gene disruption,
inactivation, random mutations, and ultimately functional changes. The modified EZ‐Tn5
transposase is highly reliable and more efficient than the wild‐type Tn5 transposase.129
The transposon insertion happens in the genomic DNA. The primers included in
the kit can be used for bi-directional DNA sequencing to determine the insertion site. The
Tn5 transposition process involves the binding of transposase monomers to the 19 bp
mosaic ends and oligomerization of the end-bound transposase monomers. The blunt end
cleavage is subsequently performed, resulting in the formation of a transposome complex
that requires Mg2+ ions from the host cell. The next step binds to the target DNA; followed
by strand transfer of the transposon 3′ ends into a 9 bp target sequence.124 The insertion
process results in small gaps which are filled by host enzymes. These gaps create short
duplications of sequences that are called target site duplications (TSD).130 This process of
transposition is summarized in Figure 1.17.
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Figure 1.17 A schematic representation of the transposition process.
A) Shows tranposition by Tn5 Transposons binding cleavage and integration followed by
the gap repair by host enzymes. Figure B)shows the enlarged version of the process that
happens in the gap repair process 120. The images belong to Lucigen Inc.
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CHAPTER 2. Probing the dynamics of AcrB through disulfide bond
formation
“Reproduce with permission from131. Copyright 2021 American Chemical Society”
2.1

Introduction
The multidrug resistance in bacteria has become one of the major threats in global

health. Bacteria have developed a mechanism to evade the attack of most commercially
available drugs. In gram-negative bacteria such as Escherichia coli, multidrug eﬄux
systems are a major mechanism that confers intrinsic and increased drug resistance to a
broad spectrum of antimicrobials.132 The overexpression of resistant-nodulation- division
(RND) superfamily member AcrAB-TolC, a tripartite complex that spans through the outer
membrane and the inner membrane, has been identiﬁed as an important mechanism leading
to multidrug resistance.133-135 AcrAB-TolC is one of the major eﬄux systems contributing
to the multidrug resistance in E. coli.
This pump has an important role in transporting substances such as antibiotics,
detergents, dyes, and free fatty acids out of the cell

46, 70, 94, 136

. In this protein complex,

TolC is a homotrimeric outer membrane channel that enables the exit of drugs from the
cell to the external medium. AcrA belongs to the membrane fusion protein (MFP) family
and exists in the periplasm. AcrB is a homotrimer inner membrane antiporter that couples
the inward proton transport with the outward substrate transport. The assembly of the
AcrAB-TolC tripartite complex has a stoichiometry of 3:6:3 for TolC:AcrA:AcrB,
respectively.49, 70
The assembled structure of the AcrAB-TolC pump complex has been revealed in
several scanning electron microscopy studies,70, 137 and more recently through cryoEM
studies, which provides insight into the molecular mechanism of transport by this pump.65,
138

Moreover, symmetric and asymmetric crystal structures of AcrB in the apo and

substrate-bound states has been determined.53, 63, 81-85 The antiporter AcrB functions as a
trimer, with 12 transmembrane α helices and a large periplasmic domain in each subunit.65
AcrB plays a pivotal role in the recognition and binding of substrates and harvests the
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proton motive force to energize drug eﬄux. In the periplasmic domain of each subunit,
there are multisite drug- binding pockets, which enable a broad range of drugs to enter and
bind, and subsequently exit through eﬄux.74, 91
The asymmetric structure of AcrB revealed novel insight into the drug binding and
transport mechanism of the pump. The AcrB periplasmic domain divides into two domains,
the porter (pore) domain and the funnel (previously known as “docking”) domain (Figure
2.1). Porter domain is further categorized into four subdomains as PN1, PN2, PC1, and
PC2. The funnel domain has two major subdomains, DC and DN. PN1 and PC2
subdomains together form a rigid β- sheet structure, in a similar way PN2 and PC1 form a
β-sheet.
Hence, in previous reports, the porter domain has been divided into two structural
subunits called PN1−PC2 and PN2−PC1.87, 88 The substrate access and transport pathway
is formed between these two structural units. The analysis of crystal structures has revealed
that a distal/deep binding pocket is located in the PN2−PC1 unit. Subdomains PC1 and
PC2 form the cleft in the bottom of the periplasmic domain, which is another drug-binding
pocket termed the proximal binding site. PN1 and PN2 form the drug exit pathway
connecting to the central pore.53, 88, 139
Substrates can access the AcrB binding pocket from the periplasm or the outer
leaﬂet of the inner membrane, through entry points/vestibules near promoters.53 More
recently, some studies suggest that certain substrates could gain access from the cytoplasm
through the central cavity or the trans- membrane-embedded external surface of the
trimer.46,

95

In the asymmetric AcrB structure, each protomer exhibits conformational

diﬀerences representing each stage of the drug transport cycle, open access (loose-L), drug
binding (tight-T), and drug extrusion (open-O)53, 55, 97. This proposed mechanism is termed
the peristaltic functional rotation mechanism 53-55, 96-99.According to the functional rotation
mechanism, the external cleft between the PC1 and PC2 subdomains opens and closes, thus
changes the distances between the protomers at the periplasmic domain. In the binding
conformation, the cleft opens wide. Also, in the extrusion conformation, the cleft closes
through the movement of the PC1 and PC2 subdomains. These conformational changes are
due to proton translocation across the trans- membrane domain and drug binding to the
porter domain.
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Disulﬁde bond trapping is an eﬀective method in studying the conformational
changes in proteins. Cysteine residues are introduced into the desired locations through
site-directed mutagenesis, and then disulﬁde bond formation is monitored. For proteins in
gram-negative bacteria, sites located in the periplasmic domain are normally chosen for
mutation since disulﬁde bonds form readily in this cellular compartment140. In this study,
we introduced inter-subunit disulﬁde bonds in the periplasmic domain of AcrB. Through
ethidium bromide (EtBr) accumulation assays and drug susceptibility assays, we have
investigated how the Cys mutation and disulﬁde bond introduced at each speciﬁc location
aﬀected the function of AcrB.

Figure 2.1Locations of the six Cys pairs in the structure of AcrB
a) Structure of an AcrB trimer showing the color-coded Cys pairs. Only mutated residues
in the light purple subunit and their partners are shown for clarity. (b) Organization of the
subdomains in the porter domain. The locations of disulﬁde bonds are shown as dots.
Structure image is rendered with pymol (https://pymol.org/2/) using the asymmetric
structure 2HRT.pdb.55
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2.2

Materials and Methods
2.2.1 Bacterial Strains, Plasmids, and Growth Conditions
Plasmid pQE70-CLAcrB, which encodes a cysless AcrB, was used as the template

to create AcrB double cys mutations141 The two intrinsic cysteines in

CLAcrB

were both

replaced by alanine to reduce the potential of nonspeciﬁc disulﬁde bond formation. The
cysless AcrB is fully functional142, 143.Mutations were introduced using the Quikchange
site-directed mutagenesis kit following the manufacturer’s instruction (Agilent, Santa
Clara, CA). Primers used in the study were listed in Table 2.1. E. coli strain BW25113 and
BW25113ΔacrB were obtained from Yale E. coli genetic resources. Bacteria were cultured
at 37 °C with shaking at 250 rpm in Luria broth (LB) media unless otherwise noted.
Table 2.1 Primers used in this study
Construct

Primer (5’-3’)

AcrB_G51C_F

CCTCCTACCCCTGTGCTGATGCGAAAAC

AcrB_G51C_R

GTTTTCGCATCAGCACAGGGGTAGGAGG

AcrB_A215C_F

GAACGCCCAGGTTTGTGCGGGTCAGCTC

AcrB_A215C_R

GAGCTGACCCGCACAAACCTGGGCGTTC

AcrB_Q123C_F

CGCAAGAAGTTTGTCAGCAAGGGGTG

AcrB_Q123C_R

CACCCCTTGCTGACAAACTTCTTGCG

AcrB_P116C_F

CAGCTGGCGATGTGTTTGCTGCCGCAAGAAG

AcrB_P116C_R

CTTCTTGCGGCAGCAAACACATCGCCAGCTG

AcrB_S167C_F

GAAAGATGCCATCTGTCGTACGTCGGGC

AcrB_S167C_R

GCCCGACGTACGACAGATGGCATCTTTC

AcrB_N70C_F

GAACAGAATATGTGCGGTATCGATAACC

AcrB_N70C_R

GGTTATCGATACCGCACATATTCTGTTC

AcrB_F316C_F

GAAGATGGAACCGTGTTTCCCGTCGGG

AcrB_F316C_R

CCCGACGGGAAACACGGTTCCATCTTC

AcrB_Q687C_F

GAGCTGATTGACTGTGCTGGCCTTGGTC

AcrB_Q687C_R

GACCAAGGCCAGCACAGTCAATCAGCTC
33

Table 2.1 (Continued)
AcrB_Q726C_F

GAAGATACCCCGTGCTTTAAGATTGATATCG

AcrB_Q726C_R

CGATATCAATCTTAAAGCACGGGGTATCTTC

AcrB_S233C_F

CAGCTTAACGCCTGCATTATTGCTCAG

AcrB_S233C_R

CTGAGCAATAATGCAGGCGTTAAGCTG

AcrB_R765C_F

CGACTTTATCGACTGTGGTCGTGTGAAG

AcrB_R765C_R

CTTCACACGACCACAGTCGATAAAGTCG

AcrB_G689C_F

GATTGACCAGGCTTGCCTTGGTCAC

AcrB_G689C_R

GTGACCAAGGCAAGCCTGGTCAATC

AcrB Seq2_R

GTGTTGCACGCATGGTAATC

AcrB Seq3_R

CCATTGCTTCACCGGTACTT

2.2.2 Drug Susceptibility Assay.
The MIC was determined for erythromycin, novobiocin, ethidium bromide (EtBr),
and tetrapheynlphosphonium chloride (TPP) following the CLSI guidelines.144 Brieﬂy,
overnight cultures of the indicated strain were diluted to a ﬁnal concentration of 105
CFU/mL in fresh Muller Hinton Broth 2 (cation adjusted) media (Millipore Sigma, St.
Louis, MO) in a 48-well microtiter plate containing the indicated compounds at two-fold
serial dilutions. Plates were incubated at 37 °C with shaking at 200 rpm for 17 h, and the
absorbance at 600 nm (OD600) were measured to identify the lowest concentrations with
no observable cell growth.
2.2.3 Protein Puriﬁcation, Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE), and Western Blot Analysis.
Five milliliters of cells were cultured overnight at 28 °C with shaking at 250 rpm.
The next morning, cells were pelleted and resuspended in 1 mL of phosphate buﬀer
containing 10 mM iodoacetamide (IAM) and phenyl- methylsulphonyl ﬂuoride (PMSF)
(1:1000 dilution of a saturated ethanol solution),and sonicated for 1 min followed by
centrifugation for 10 min at 15 000 rpm. The supernatant was removed, and cell pellets
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were resuspended in 0.2 mL of phosphate-buﬀered saline (PBS) + 2% Triton-X100
containing 10 mM IAM. The samples were incubated at room temperature with
shaking for 45 min and centrifuged again for 10 min. The supernatant was used for SDSPAGE and Western blot analysis.
For Western blot analysis, a disulﬁde bond was reduced either by incubating with
10% β-mercaptoethanol (BME) for 10 min or 50 mM dithiothreitol (DTT) for 1 h as
indicated. After transferring to the poly(vinylidene diﬂuoride) (PVDF) membrane, protein
bands were detected using an anti-AcrB polyclonal (Rabbit) antibody raised to recognize
a C-terminal peptide corresponding to residues number 1036−1045145.The membrane was
then washed and incubated with an alkaline phosphatase-conjugated Goat anti-Rabbit
secondary antibody. The BCIP/NBT (5-bromo-4-chloro-3′-indolyphosphate and nitro-blue
tetrazolium) solution was used to stain the membranes.
2.2.4

EtBr Accumulation Assay.

The EtBr assay was performed following the established procedure with slight
modiﬁcation.146 Brieﬂy, cells were grown in 15 mL of LB media until the mid-log phase
(OD600 of 0.6−0.8). The bacteria were then centrifuged at 3000g for 15 min and washed,
the cell suspension was loaded into a cuvette and monitored using a ﬂuorescence
spectrometer (Perkin-Elmer LS 550), at excitation and emission wavelengths of 520 and
590 nm, respectively. After ∼40 s, 1 mL of EtBr was added to a ﬁnal concentration of 10

μM and to make ﬁnal OD600 of cell suspension 1.0, and the emission was monitored for an
additional 600 s. For the samples with DTT treatment, cells were incubated with 50 mM
freshly prepared DTT for 1 h at room temperature before loading into the cuvette.
2.3

Results and discussion
2.3.1 Inter-Subunit Disulﬁde Cross-Linking Construction.
The functional rotation mechanism proposed ﬁrst in 2006 highlighted the

importance of AcrB conformational change during substrate eﬄux.53, 55 During this threestep mechanism, each protomer of the AcrB trimer adopts a distinct conformation. The
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conformational changes are driven by the proton translocation into the cytoplasm from the
periplasm through a pathway along the transmembrane domains of AcrB. As discussed
above, the relative locations of the periplasmic subdomains change during the functional
rotation. This cycling mechanism suggested that AcrB acts as a peristaltic pump through
the opening and closing of the drug-binding pockets and access to the TolC. Furthermore,
it has been speculated that the conformational changes caused by substrate binding and
proton motive force may transfer through AcrA bound to the cleft.53 Using the online
server of “Disulﬁde by Design 2.0” (http://cptweb.cpt.wayne.edu/DbD2/),147 we identiﬁed
six sites on the inter-subunit interface to introduce Cys pairs and used these pairs to study
the ﬂexibility and relative conformational change at the corresponding locations.
The locations of the six cys pairs are shown in Figure 2.1. Residues G51, N70,
Q123, and P116 are located in the PN1 subdomain. S167 and F316 are in the PN2
subdomain. Q687 and G689 are in the PC2 domain. A215 and S233 exist in the longextended loop that penetrates deep into the neighboring subunit. R765 exists at the tip of a
long loop formed by the C- terminal half of AcrB, which is equivalent to the extended loop
in the N-terminal half of AcrB. Q726 is located at the boundary between PC2 and the DC
domain. These introduced cysteine pairs were expected to form crosslinks at the intersubunit interface between the PN1−PN2 subdomains (N70C/ S167C), PN1−PN1
subdomains (P116C/Q123C), PN2−PC2 subdomains (F316C/Q687C), the loop and DC
subdomain (S233C/Q726C), the loop and PN1 subdomain (G51C/ A215C), and the PC2DC subdomains (G689C/R765C). From the four subdomains in the porter domain,
PN1−PC2 and PN2−PC1 form the binding pockets. The proximal binding site involves
PC1−PC2 interaction, and PN1−PN2 is important in the exit stage of the substrate.87
Furthermore, V105C in the PN1 domain, which has been reported to form a disulﬁde bond
in an AcrB trimer, was used as a control to reveal the migration position of a disulﬁde
bond-linked dimer.148 Cell lysate samples prepared from BW25113ΔacrB and
BW25113ΔacrB transformed with plasmid pQE70-CLAcrB were used as the controls. In
CLAcrB,

two intrinsic Cys residues were replaced with Ala.
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Figure 2.2 Western blot analysis of disulﬁde bond formation in AcrB mutants.
(a) Double-cysteine mutants, with nonreduced samples shown on the left and reduced
samples shown on the right. (b) Single-cysteine mutant samples without reduction. Bands
in the molecular weight marker are highlighted using black arrows. From top to bottom,
the arrows correlate with molecular weights of 245, 190, 135, 100, 80, and 58 kDa.
Table 2.2 Percentage of Oligomers in Mutants
AcrB

N70C/

P116C/

G51C/

S233C/

F316C/

G689C/

mutants

S167C

Q123C

A215C

Q726C

Q687C

R765C

oligomer

58.3 ±

53.2 ±

60.6 ±

69.1 ±

68.9 ±

74.9 ±

57.9 ±

5.4

11.4

6.8

6.6

6.4

6.8

13.2

(%)

V105C

2.3.2 Detection and Quantiﬁcation of Disulﬁde Bond Formation.
The formation of disulﬁde crosslinks was analyzed using Western blot analysis
with an anti-AcrB antibody. In the absence of the reducing reagent, all six pairs formed
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oligomers (Figure 2.2a). IAM was added before the lysis of the cells to prevent the
formation of a disulﬁde bond during the cell lysis and analysis process. An unknown band
close to the 58 kDa marker could be observed in all samples, including the negative control.
This band has been observed in previous studies using the same antibody149. It could be an
unknown protein that also contains a stretch of a similar peptide like the one used to raise
the antibody. Since this nonspeciﬁc band is well separated from those of the AcrB band, it
does not interfere with the interpretation of the data. The intensity of this nonspeciﬁc band
also served as a loading control. Otherwise, the cell lysate prepared from BW25113ΔacrB
did not have a protein band, conﬁrming the good speciﬁcity of the antibody. The
background construct CLAcrB migrated with an apparent molecular weight of ∼100 kDa,

consistent with a monomer. The oligomers formed by other Cys pair constructs are likely
dimer or trimers. The treatment with 10% β-mercaptoethanol led to a complete reduction
of oligomers to monomers, further conﬁrming that the high-molecular-weight bands were
formed due to disulﬁde bonds. The expression level of most Cys pair constructs was similar
to that of CLAcrB, while the P116C/Q123C pair seemed to express signiﬁcantly less.
Furthermore, Western blot analysis of single-cysteine mutations revealed that no
high-molecular-weight oligomers were present, conﬁrming that disulﬁde bonds were
formed between the pair of cysteines (Figure 2.2b). The mobility of oligomers was diﬀerent
for diﬀerent Cys pairs. In an AcrB trimer containing a Cys pair at each inter-subunit
interface, there are four possible products: a circular trimer trapped with three disulﬁde
bonds, a linear trimer trapped with two disulﬁde bonds, and a disulﬁde bond trapped dimer
plus a monomer. We included V105C in this study as a mobility marker, as it would migrate
as a monomer and a disulﬁde bond-linked dimer. Through comparison with the V105C
dimer bands, it appeared that the mobility of P116C/Q123C, G51C/A215C, and
N70C/S167C oligomers seemed to be closer to that of the V105C dimer with an apparent
molecular weight of ∼200 kDa, and the oligomer formed in F316C/Q687C,

G689C/R765C, and S233C/Q726C constructs migrated slower than the V105C dimer and
with apparent molecular weight larger than the highest band in the marker (245 kDa).
Disulﬁde bond introduced at diﬀerent locations has a clear impact on the mobility of the
protein.
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While all Cys pair mutants formed a signiﬁcant portion of disulﬁde bond-linked
oligomers, they all have a monomer population. We used the software ImageJ to analyze
the percentage of crosslinked products in each of the mutants.150 The percentage of
crosslinked oligomers ranged from 53 to 75% (Table 2.2). Several factors may aﬀect the
level of disulﬁde bond formation between two residues in the structure of a protein, the
distance between the residues, the compatibility of the geometry of the Cys pair to that of
a disulﬁde bond, and the intrinsic ﬂexibility of the relevant protein regions including both
the backbone and the side chain (the B-factor).147 We noted that one of the Cys pairs we
created in this study, S233C/Q726C, have been reported in a previous study by Seeger et
al.151. The previously reported cross-linking level of 17.0 ± 0.4% is signiﬁcantly lower than
our observation (69.1 ± 6.6). The diﬀerence could be due to diﬀerences in the cell culture
and sample procession procedure. An extra band could be observed at ∼120 kDa, which
disappeared upon reduction. We speculate that this could be a diﬀerent protein

conformation that was trapped by the disulﬁde bond. This band could also be observed,

although at a lower concentration, in the study by Seeger et al. 151
2.3.3 Functional Analysis of Cysteine Mutations through Drug Susceptibility
Assay.
To evaluate the impact of the introduced Cys mutations and subsequent formation
of disulﬁde bond on AcrB function, we measured the MIC of BW25113ΔacrB transformed
with plasmids encoding each single or double Cys mutant. Four known AcrB substrates
were used in the assay (Table 2.3). If relative movement at the respective sites is important
for eﬄux, we expect the formation of disulﬁde bonds at these sites would aﬀect protein
function.
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Table 2.3 MIC (μg/mL) Values for E. coli Containing Single- or Double-Cysteine AcrB
Mutants
Plasmid

novobiocin

erythromycin

EtBr

TPP

none

8

4

16

16

CLAcrB

128

128

256

512

S167C

64

64

128

512

N70C

128

64

128

512

N70C/S167C

64

64

128

512

Q123C

64

64

128

256

P116C

64

64

256

512

P116C/Q123C

32

64

128

256

G51C

64

128

128

256

A215C

128

128

256

512

G51/A215C

64

128

128

256

Q726C

64

128

256

512

S233C

128

128

256

512

S233C/Q726C

64

128

256

512

F316C

64

64

256

512

Q687C

128

128

256

512

F316C/Q687C

16

16

32

32

R765C

64

64

256

512

G689C

64

64

256

512

G689C/R765C

32

32

128

256

V105C

16

32

64

128

V105G

32

32

128

128

The behavior of the constructs could be clustered into two groups. In the ﬁrst group,
the Cys pair mutants behaved similarly as the less active single mutant for most of the
substrates tested. Four out of the six constructs belonged to this group. Strains containing
N70C, S167C, or the N70C/ S167C double mutant all had similar MIC values as the
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positive control CLAcrB for TPP, while the MIC of the other three compounds was reduced
by half. The Q123C mutation reduced the MIC of all four drugs tested by half, while the
P116C mutation only aﬀected the MIC of novobiocin and erythromycin. The double
mutant P116C/Q123C behaved similar to the single Q123C mutant except for novobiocin,
for which the MIC was further reduced by 2-fold. The G51C single mutation led to a 2fold reduction of the MIC of G51C/A215C double mutation had similar MIC as the G51C
single mutant for all four test compounds. Strains containing Q726C, S233C, or the
corresponding double mutant had similar MIC as the positive control for all substrates
except for novobiocin. The Q726C single mutant and the double mutant displayed a 2- fold
reduction in MIC for novobiocin.
The other two pairs belong to the second group. For the F316C/Q687C pair and the
G689C/R765C pair, strains containing the double mutants displayed lower MICs for all
four compounds tested than the corresponding single mutants. While the Q687C mutation
did not lead to an observable reduction of activity, the F316C mutation led to a 2-fold
reduction of MICs for novobiocin and erythromycin. The F316C/Q687C double mutant
displayed an 8- to 16-fold reduction in MIC for all substrates. Similarly, R765C and G689C
single mutants had similar activity as the positive control for EtBr and TPP, and a 2-fold
reduction of MIC for erythromycin and novobiocin. The double mutant showed lower
activity toward all four compounds with a reduction in MIC of 2- to 4-fold. For this group,
there is a possibility that the observed higher susceptibility of the cysteine double mutants
is due to the restriction of conformational change resulted from crosslinks, which impaired
the eﬄux activity of AcrB. We have also included V105C and V105G mutants in this study.
As expected, mutation of V105 led to a signiﬁcant reduction of eﬄux activity as the MICs
of all four compounds tested were reduced. For novobiocin and EtBr, the MICs of the strain
containing V105C were 2-fold lower than that of the V105G.

2.3.4 Restoration of the Activity by Dithiothreitol (DTT) Detected Using EtBr
Accumulation Assay.
If the previously observed higher drug sensitivity is a result of disulﬁde bond
formation, the reduction of the disulﬁde bonds should restore the eﬄux activity. This was
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investigated using the EtBr accumulation assay. We found that DTT at 10 mM could not
fully reduce the disulﬁde bonds formed in our AcrB constructs, even with 4 h incubation
(Figure 2.3). While the portion of monomers did increase after the treatment, clear
oligomer bands could still be observed in all cases. And for some samples, multiple
oligomer bands could be observed after this treatment, which are likely partially reduced
oligomers. When incubated with 50 mM DTT, disulﬁde bonds could be completely
reduced after 1 h incubation (Figure 2.3). Thus, this higher DTT concentration was used
for the accumulation assay.

Figure 2.3 Anti-AcrB Western blot analysis of double-cysteine AcrB mutants under
diﬀerent reduction conditions.
Left: Reduced with 10 mM DTT and incubated for 4 h at room temperature. Oligomers are
only partially reduced. Right: Reduced with 50 mM DTT and incubated for 1 h at room
temperature. Oligomers are fully reduced. The bands in the molecular weight marker are
highlighted by black arrows. From top to bottom, the molecular weights are 245, 190, 135,
and 100 kDa.
Cells containing the indicated plasmids were prepared as described in Section 2.2.4 for the
EtBr accumulation assay. We included all six pairs, as well as V105C, in the study for
comparison. For four out of the six Cys pair constructs, the DTT treatment did not lead to
a signiﬁcant diﬀerence in the rate of EtBr accumulation (Figure 2.4). However, for the
other two pairs, F316C/Q687C and G689C/R765C, reduced samples exhibited notably
lower accumulation of EtBr, indicating that the formation of a disulﬁde bond contributed
signiﬁcantly to the reduced activity. This indicated that the reduction of disulﬁde crosslinks
by DTT at these two locations had partially restored the eﬄux activity (Figure 2.4d,e). In
a previous study by Takatsuka and Nikaido, the introduction of the F316C/ Q687C double
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mutant has also been shown to greatly reduce the eﬄux activity, consistent with our
observation97.

Figure 2.4 EtBr accumulation assay of all double-cysteine mutants with or without
reduction.
(a) Negative control BW25113ΔacrB (blue no DTT, red with DTT) and positive control
BW25113ΔacrB expressing plasmid-coded CLAcrB (orange no DTT, brown with DTT).
(b) BW25113ΔacrB expressing AcrB mutants N70C/S167C (blue no DTT, red with DTT)
or P116C/Q123C (orange no DTT, brown with DTT). (c) BW25113ΔacrB expressing
AcrB mutants G51C/A215C (blue no DTT, red with DTT) or S233C/Q726C (orange no
DTT, brown with DTT). (d) BW25113ΔacrB expressing AcrB mutant F316C/Q687C (blue
no DTT, red with DTT). (e) BW25113ΔacrB expressing AcrB mutant
G689C/R765C (blue no DTT, red with DTT).

2.5 V105 Mutations and Eﬄux.
V105C is located in a helix close to the threefold axis of the AcrB trimer and forms
a disulﬁde bond.148 It was speculated that the formation of a disulﬁde bond restricted the
conformational changes to reduce the eﬄux activity. In our study, we observed low MIC
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values (Table 2.3) for novobiocin and erythromycin, consistent with previous studies,
indicating that the mutation signiﬁcantly impacted AcrB activity.148 However, the DTT
treatment reduced the dimer but only led to a modest reduction of EtBr accumulation in
BW25113ΔacrB expressing V105C (Figure 2.5). To further investigate the potential role
of the disulﬁde bond in activity, V105 was mutated to Gly. Accumulation of EtBr in
BW25113ΔacrB containing V105G was higher than that in the positive control, indicating
that the replacement of Val itself is detrimental to function. This result is consistent with
the MIC measurement. Accumulation of the strain containing V105C was higher than that
in the strain containing V105G, suggesting that the formation of the disulﬁde bond further
impaired eﬄux. Upon reduction, accumulation in the V105C strain was reduced to be more
similar to the accumulation in the V105G strain.

Figure 2.5 Analysis of V105C and V105G.
(a) Anti-AcrB Western blot analysis of V105C and V105G, showing the formation of a
disulﬁde bond in V105C but not V105G. The molecular weight of bands in the marker is
highlighted by black arrows. From top to bottom: 245, 190
2.4

Conclusions
The structure of the entire AcrABZ-TolC complex has been revealed using

cryoEM.65, 152 More recent studies illustrated the in situ structure of the complex in E. coli
cells overexpressing the pump components.138 While these structure insights have led to
the answer of many questions related to the mechanism of eﬄux by the RND pumps,
studies on the dynamic aspects of the pumps lag far behind. As any molecular machines,
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the AcrAB-TolC system undergoes a conformational change to carry out eﬄux. While the
combination of structures, which are snapshots of proteins, and computational simulation
cast lights on how proteins move, experimental testing of the simulation movies is critical.
Based on the crystal structure of AcrB, we designed and engineered six Cys pairs to
examine the consequence of these structure staples on its eﬄux activity. We found that for
four pairs, the formation of a disulﬁde bond did not seem to have much impact on eﬄux,
as the double mutant behaved similarly as the less active single mutants. Relative intersubunit movement at these sites does not seem to be required for eﬄux.
For the other two pairs, the double mutants are less active than the individual single
mutants, which could be potentially due to the restriction eﬀect from the disulﬁde bond
that either restricted relative movement of neighboring subunits or locked the subunits in a
conformation incompatible with substrate binding and/or translocation. While the activity
of the eﬄux pump is most conveniently evaluated using the MIC assay, the eﬀect of
disulﬁde bond on activity could not be measured this way since the high concentration of
reducing reagent that is necessary to eﬀectively reduce the disulﬁde bonds would inhibit
E. coli growth. Alternatively, EtBr eﬄux could be monitored using cells containing
reduced or nonreduced AcrB Cys pair constructs. We found that for two pairs, F316C/
Q687C and G689C/R765C, reduction of the disulﬁde bond signiﬁcantly improved eﬄux,
conﬁrming the functional relevance of conformational ﬂexibility at these sites. There
appears to be a discrepancy between the apparent percentage of cross-linking with the level
of reduced activities in these double mutants, which is most likely explained by the
diﬀerent growth phases the cells were harvested for the two types of experiments. For the
activity (MIC) measurement, the proliferation of cells was monitored in the presence of
test compounds. For the EtBr accumulation assay, mid-log phase cells were taken and used
in the study, whereas for the cross- linking analysis, overnight cultures were taken, and
those cells were in the stationary phase and took longer time for disulﬁde formation.
Apart from the interference by disulﬁde bond formation on the function of AcrB,
the reduction of the activity of the Cys pairs could be due to an unfavorable conformation
of the disulﬁde dimers that interfere with the substrate binding and transport activity.
Interestingly, the two sites with high impact on activity are located close to each other, with
one containing Q687C and the other containing G689C, just two residues apart (Figure 2.1,
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brown and yellow dots). While F316C/ Q687C forms a disulﬁde bond at the interface
between the PN2 and PC2 subdomain of the neighboring subunit (brown), G689C/R765C
linked the PC2 subdomain to the tip of the long loop formed by the C-terminal half of the
neighboring subunit.
Since each subunit in an AcrB trimer contains a separate and complete set of
substrate binding residues and translocation pathway, a conformational change that is
involved in substrate binding and extrusion should be localized more to the inside of a
subunit. Yet, relative inter-subunit conformational change has been reported in several
cases to be critical for AcrB function, likely due to the functional rotation mechanism in
which the trimer needs to undergo conformational change simultaneously. Thus, some of
the sites that are located at the inter- subunit interface are expected to be the “sensor” sites
that need to play the role of coordinating the movement. While in other sites, including
several sites described in this, and V225C/ A777C, R558C/E839C, V32C/A299C, and
I235C/K728C reported in previous studies (Table 2.4), Cys substitution and disulﬁde bond
formation do not have a clear impact on functions.151 These could be sites that maintain
close contact throughout the functional rotation mechanism to maintain AcrB as a tightly
associated, integrated, functional trimer.
Table 2.4 Engineered Disulﬁde Bonds in AcrBa
Res1

Res2

oligomer (%)

activity level

citation

G51

A215

60.6 ± 6.80

+++

this study

Q123

P116

53.2 ± 11.4

++

S167

N70

58.3 ± 5.4

+++

F316

Q687

68.9 ± 6.4

−

Q726

S233

69.1 ± 6.6

+++

R765

G689

74.9 ± 6.8

−

V105C

V105C

57.9 ± 13.2

+

Q229

R586

46.4 ± 0.5

++

R558

E839

−9.5 ± 4.7e

+++

Inter-Subunit
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Table 2.4 (Continued)
S562

T837

15.4 ± 1.3e

+

S132

A294

41.6 ± 0.6

+

V32

A298

41.3 ± 1.2

+

V32

A299

18.1 ± 1.0

+++

Q726

S233

17.0 ± 0.4

+++

I235

K728

23.8 ± 0.6

+++

V225

A777

80.2 ± 1.3

+++

Q229

T583

69.4 ± 0.5

+

D566

T678

N/A

+

F666

T678

N/A

−

F666

Q830

N/A

+

F316

Q687

N/A

++

F316

A688

N/A

+

F316

G854

N/A

−

V32

I390

82.5 ± 6.8

+++

T44

T91

100.7 ± 3.0

+++

M184

V771

76.2 ± 4.9

+++

T199

T749

82.7 ± 2.9

+++

I335

A995

51.7 ± 0.8

+++

T574

A627

102.9 ± 6.8

Q726

G812

97.7 ± 5.0

G570

A627

+++

F572

A627

+++

V576

A627

+++

L578

A627

+++

97, 140

97

Intra-Subunit
141

+++
+++

+++: MIC equals to 50−100% of the wild-type MIC. ++: MIC equals to 25% of the
wild-type MIC. +: MIC equals to 12.5% or less of the wild-type MIC. −: MIC close to
the negative control MIC
a
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CHAPTER 3. Insight into the AcrAB-TolC complex assembly process
learned from competition studies
Reproduced in parts with permission from153, antibiotics; published by MDPI 2021.
3.1

Introduction
Antimicrobial resistance, especially multidrug resistance in bacterial pathogens, is

among the top 10 global threats to humanity 15. Among the large array of different defense
mechanisms adapted by bacteria, the overexpression of efflux pumps has a significant role
in conferring multidrug resistance. AcrAB-TolC is one of the most extensively studied
efflux pump systems in Gram-negative bacteria, playing a crucial role in the multidrug
resistance in bacteria such as Eshcherichia coli 57 , 69, 154. AcrAB-TolC is a member of the
resistance nodulation division (RND) superfamily. AcrAB -TolC efflux pump confers
resistance to a broad spectrum of antimicrobial compounds including β-lactams,
tetracycline, novobiocin, and fluroquinolones
consists of three major protein components

51, 52

135, 136

. This tripartite efflux transporter

, an outer membrane channel TolC, a

periplasmic adaptor protein (PAP) AcrA, and an inner membrane proton-driven antiporter
AcrB 70, 74, 87, 137. TolC forms a channel that spans the outer membrane and acts as the exit
pathway of substrates translocated from the inner membrane and the periplasmic space.
AcrA has function in stabilizing the connection between the two membrane components
TolC and AcrB

58, 59

. The RND transporter protein AcrB is responsible for substrate

recognition and energy transduction. Upon binding of a substrate, AcrB uses the energy
from the proton flow down its concentration gradient through a proton translocation
pathway in the transmembrane domain to drive the conformational change necessary to
move the substrate upward toward the exit tunnel

56, 57

. TolC is shared by several efflux

systems, hence E. coli strains deficient in TolC are more sensitive to a wider variety of
chemicals (e. g. detergents, drugs, bile salts, and organic solvents) 60, 61.
With the dedication of many research groups, the structure and mechanism of drug
efflux by the RND pumps have been brought to light. The first crystal structure of the pump
component was determined for TolC by Koronakis et al. 64 in 2000. TolC is a trimer with
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an overall length of 140 Å with 40 Å in the β-barrel domain mainly composed of β strands,
and 100 Å in the periplasmic domain mainly composed of α-helices. The periplasmic end
of the TolC tunnel is sealed at the resting state, which likely opens by an allosteric protein–
protein interaction mechanism

138

. In 2002, Murakami et al. first reported the crystal

structure of AcrB, followed by the proposal of the functional rotation mechanism 53, 63, 96.
Later in 2006, Mikolosko and coworkers determined the crystal structure of AcrA. In
contrast to the trimeric TolC and AcrB, AcrA forms a hexamer in the pump assembly 62.
The assembled pump structure was first proposed as the “deep interpenetration model”,
which shows that AcrB and TolC have direct interactions with AcrA wrapped around on
the outside to strengthen the interaction

71

. More recently, Wang et al. proposed a new

model based on Cryo-EM studies, known as the “tip-to-tip model”. In this model, AcrA
hairpins form a barrel-like conformation, contacting TolC in a tip-to-tip arrangement 65, 72.
The recent determination of the complex structure first by cryo-EM, then by X-ray
crystallography, confirmed the tip-to-tip model 55, 63, 82, 83, 91, 136, 138. Energy does not seem
to be required to assemble the AcrAB-TolC complex and AcrAB could interact with the
TolC channel to form a AcrAB-TolC complex even in the absence of known substrate 77.
The dynamic process that leads to the formation of the complex is still elusive.
The dominant negative effect describes the phenomena in which an excess of a
functionless mutant of a protein in the presence of its wild type counterpart, reduces the
observed activity due to competition from the mutant for interaction with functional
partners of the protein of interest. In the AcrAB-TolC complex, over-expression of
functionless AcrB or AcrA mutant in wild type E. coli strains is expected to drastically
reduce the assembly of functional efflux complex, and thus reduce the efflux activity and
increase the sensitivity to substrate compounds. However, we tested the overexpression of
several functionally defective mutants in the wild type E. coli strain, but did not observe
the expected level of reduction. We speculate that the assembly of the AcrAB-TolC is a
precisely controlled process involving delicate proof-reading procedures.

49

3.2

Materials and Methods
3.2.1 Bacterial strains, plasmids and growth conditions
Escherichia coli BW25113 and BW25113∆acrB were obtained from Yale E. coli

genetic resources. BW25113∆acrAB was constructed using E. coli gene deletion kit (Cat
#K006, Gene Bridge) following the manufacturer’s protocol. Plasmids pBAD33-AcrB was
created in our previous study155. To create the plasmid pBAD33-AcrAB, acrAB gene was
amplified from genomic DNA of BW25113 and cloned into pBAD33 by following the fast
cloning method described previously by Li et al.156. Plasmids pBAD33-AcrB, and
pBAD33-AcrAB were used as the templates to create respective mutations discussed
below. Mutations were introduced using the Quikchange Site Directed Mutagenesis Kit
following manufacturer’s instruction (Agilent, Santa Clara, CA). Primers used in this study
mentioned in Table 3.1. Bacteria were cultured at 37oC with shaking at 250 rpm in Luria
broth (LB) media unless otherwise noted.
Table 3.1 Primers used in this study
Construct

Primer (5’-3’)

AcrB D408A-F

CATCGGCCTGTTGGTGGATGCCGCCATCGTTGTGGTAG

AcrB D408A-R

CTACCACAACGATGGCGGCATCCACCAACAGGCCGATG

AcrB K940A-F

CCATTGGGTTGTCGGCGGCTAACGCGATCCTTATCG

AcrB K940A-R

CGATAAGGATCGCGTTAGCCGCCGACAACCCAATGG

AcrB R971A-F

CTTGATGCGGTGCGGATGGCATTACGTCCGATCCTGATG

AcrB R971A-R

CATCAGGATCGGACGTAATGCCATCCGCACCGCATCAAG

AcrB T978A-F

CGTCCGATCCTGATGGCCTCGCTGGCGTTTATCCTC

AcrB T978A-R

GAGGATAAACGCCAGCGAGGCCATCAGGATCGGACG

AcrB F178A- F

GGGTGATGTTCAGTTGGCCGGTTCACAGTACGCGATG

AcrB F178A- R CATCGCGTACTGTGAACCGGCCAACTGAACATCACCC
AcrB I278A-F

GGTGAGAACTACGACATCGCCGCAGAGTTTAACGGCCAAC

AcrB I278A-R

GTTGGCCGTTAAACTCTGCGGCGATGTCGTAGTTCTCACC

AcrB F610A -F

CAACGTTGAGTCGGTGGCCGCCGTTAACGGCTTCGGC
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Table 3.1 (Continued)

AcrB F610A -R GCCGAAGCCGTTAACGGCGGCCACCGACTCAACGTTG
AcrA P57C-F

CAG ATC ACA ACC GAG CTT TGT GGT CGC ACC AGT GCC
TAC

AcrA P57C-R

GTA GGC ACT GGT GCG ACC ACA AAG CTC GGT TGT GAT
CTG

AcrA T217C-F

CCG ATC GTT GAT GTG TGT CAG TCC AGC AAC GAC TTC

AcrA T217C-R

GAA GTC GTT GCT GGA CTG ACA CAC ATC AAC GTA GAT
CGG

AcrB N191C-F

CGT ATC TGG ATG AAC CCG TGT GAG CTG AAC AAA TTC
CAG

AcrB N191C-R

CTGGAATTTGTTCAGCTCACA CGG GTT CAT CCA GAT
ACG

AcrB S258C-F

CTG AAA GTG CAG GAT TGT CGC GTG CTG CTG CGT TCC

AcrB S258C-R

GGA ACG CAG CAC GCG ACA ACC ATC CTG ATT CAG TTT
CAG

3.2.2 Drug susceptibility assay
The minimum inhibitory concentration (MIC) was determined for erythromycin,
novobiocin, ethidium bromide (EtBr), rhodamine 6G (R6G) and tetraphenylphosphonium
chloride (TPP) following the CLSI guidelines.144 Briefly, overnight cultures of the
indicated strain were diluted to a final concentration of 105 CFU/mL in fresh Muller Hinton
Broth 2 (cation adjusted) media (Millipore Sigma, St.Louis, MO) in a 48 well microtiter
plate containing the indicated compounds at two-fold serial dilutions. Plates were
incubated at 37oC with shaking at 160 rpm for 17 hrs the absorbance at 600 nm (OD600)
were measured to identify the lowest concentrations with no observable cell growth.

51

3.2.3 Protein expression, SDS-PAGE and Western blot analysis
For expression test, 5 mL of cells were cultured overnight at 37oC with shaking at
250 rpm. In the next morning, the cell was inoculated with a 100-fold dilution into a 5 ml
fresh LB media supplemented with antibiotics and grow until ~ OD600 1.0. Cells were
pelleted and resuspended in 1 mL phosphate buffer containing phenylmethylsulphonyl
fluoride (PMSF) (1:1000 dilution of a saturated ethanol solution) and sonicated for 1 min
followed by centrifugation for 10 mins at 15,000 rpm. The supernatant was removed, and
cell pellets were resuspended in 0.1 mL PBS containing 2% Triton-X100. The samples
were incubated at room temperature with shaking for 45 mins and centrifuged again for 10
mins. The supernatant was used for SDS-PAGE and Western blot analysis. For studies of
disulfide bond formation, iodoacetamide (IAM) was added to a final concentration of 20
mM in all buffers. To reduce disulfide bond, β-mercaptoethanol (BME) was added to a
final concentration of 2% followed by incubation at room temperature for 30 mins.
For Western blot analysis, after transferring to the PVDF membrane, protein bands
were detected using an Anti-AcrB polyclonal (Rabbit) antibody raised to recognize a Cterminal peptide corresponding to residues number 1036-1045145. The membrane was then
washed and incubated with an alkaline phosphatase conjugated Goat anti-Rabbit secondary
antibody.

The

BCIP/NBT

(5-bromo-4-chloro-3'-indolyphosphate

and

nitro-blue

tetrazolium) solution was used to stain the membranes.
For AcrAB dissociation experiment, BW25113 or BW25113ΔacrA containing
plasmid pBAD18-AcrA was cultured to the log phage (OD600 0.8) and arabinose was
added to a final concentration of 0.2% (w/v) to induce the expression of AcrA for 50 min.
The cells were then pelleted, washed, and resuspended with fresh LB. An aliquot of cell
culture was collected, pelleted, and stored at −20 °C. The rest of the cell culture was
returned to the shaker and cultured for 5 h, and another aliquot of sample was collected,
pelleted, and stored at −20 °C. The last sample was collected at 17 h. OD600 of the samples
were measured and used to adjust the sample volume collected to ensure that the same
number of cells were used for each time point. All pellets were resuspended and sonicated
to lyse the cells. After centrifugation, the pellet was extracted using PBS + 2% Triton for
2 h. The mixtures were centrifuged again and the supernatants were incubated with Ni
beads for 40 min, followed by washing with the same buffer supplemented with 50 mM
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imidazole, and finally eluted with the same buffer supplemented with 500 mM imidazole.
For DSP crosslinking experiments, the cell pellet was washed and then resuspended in PBS
buffer. DSP was added to a final concentration of 1 mM, and the mixture was incubated at
room temperature for 30 min. To stop the reaction, a Tris-Cl buffer (pH 8.0) was added to
a final concentration of 20 mM. Cells were then pelleted, and proteins were purified
similarly as described above. To break the disulfide bond in DSP, DTT was added to the
sample to a final concentration of 10 mM. For Western blot analysis, Anti-AcrB polyclonal
(Rabbit) antibody or Anti-AcrA antibody used respectively. All experiments were repeated
at least three times.
3.3

Results and discussion
3.3.1 AcrB mutants defective in proton transport

Several key residues have been identified in the AcrB transmembrane domain, forming the
proton translocation pathway 55, 63, 88, 139, 157-161. We have created single alanine replacement
mutations at each of these sites to obtain mutants AcrB-D407A, AcrB-D408A, AcrBK940A, AcrB-T978A, and AcrB-R971A

158, 160

. The plasmid encoding of these mutants

was first transformed into the BW25113∆acrB strain to examine their efflux activity (Table
1). As expected, the minimum inhibitory concentrations (MICs) of most examined
substrates against the strains containing the mutants were the same as those against the
strains without plasmids. The only mutant that displayed significant activity is T978A,
which remained partially active. As a positive control, we showed that transformation with
a plasmid encoding the wild type AcrB completely restored the efflux activity with MIC
values similar to a wild type BW25113 strain. Next, we transformed these plasmids into
the wild-type BW25113 strain and measured the MIC. We expected the AcrB mutants to
compete with the genomic AcrB in binding and interaction with genomic AcrA and/or
TolC, thus reduce the number of functional efflux complexes and subsequently the drug
susceptibility. However, we observed a two-fold reduction of MIC value in some cases,
and no reduction others, which is consistent with an earlier study reporting the modest
reduction of substrate susceptibility when AcrB-D407A was over-expressed in a wild -type
E. coli strain (Table 3.2) 145.
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Table 3.2 MIC values (µg/mL) of BW25113 or BW25113∆acrB strains containing the
indicated plasmid encoding AcrB mutants defective in proton translocation pathway.
Substrate 1

NOV

ERY

TPP

EtBr

R6G

NA

/

4

4

4

8

8

1

WT

128

64

256

128

256

4

D407A

4

4

4

8

8

ND

D408A

4

4

4

8

8

ND

K940A

8

4

4

8

8

ND

R971A

8

4

4

8

16

ND

T978A

8

8

16

32

128

ND

/

256

64

1024

512

1024

4

WT

512

128

1024

512

1024

4

D407A

128

64

1024

256

512

4

D408A

128

64

1024

512

1024

4

K940A

256

64

1024

512

1024

4

R971A

128

32

1024

512

1024

4

T978A

256

64

1024

512

1024

2

BW25113∆acrB
containing

BW25113 containing

1

NOV, novobiocin. ERY erythromycin, TPP tetraphenylphosphonium, EtBr ethidium

bromide. R6G, rhodamine 6G, NA, nalidixic acid. ND, not determined.
We conducted the MIC assay under the basal expression condition without
induction to avoid the potential artifact that may arise from over-expression. To examine
how much of each mutant actually expressed under the basal condition, we prepared
samples from BW25113 containing different plasmids, and compared the expression level
from the plasmid to the level of genomic AcrB. Even without induction, under our
experimental condition, the plasmid-encoded mutants were expressed at a much higher
level (5–20 folds higher) compared to the level of the genomic AcrB (Figure 3.1a). This
result indicates that the lack of impact on drug susceptibility is not due to the lack of
54

expression. Even presented at a large excess, the mutants were not effective in disrupting
the normal efflux activity.
Single mutations on the proton relay pathway do not significantly affect the overall
structure of AcrB. The crystal structure of a couple of these mutants have been determined
using X-ray crystallography 158, 162. All mutants form trimeric structures similar to those in
the wild-type AcrB 158. To examine if a mutant defective in proton translocation could still
bind AcrA, we used two inter-subunit disulfide bonds as our yardsticks to probe the
interaction between AcrA and AcrB. We first constructed a plasmid expressing both AcrA
and AcrB (pBAD33-AcrAB), then introduced a pair of cysteines, one in AcrA and the other
in AcrB: AcrA-P57C/AcrB-N191C, and AcrA-T217C/AcrB-S258C. These residues are
predicted to be close to each other according to the “Disulfide by Design 2.0” (http://
cptweb.cpt.wayne.edu/DbD2/ (accessed on 06/01/2019))147. The formation of disulfide
bond linked AcrA-AcrB complex was confirmed using anti-AcrA and anti-AcrB Western
blot (Figure 3.1b). A high molecular weight complex could be detected in both blots,
which disappeared upon incubation with β-mercaptoethanol (BME). The disulfide bondlinked species migrated slightly differently in the gel, likely due to differences in the
conformations of the two complexes under the gel running condition. Mutation and
disulfide bond formation did not significantly impair efflux activity, as revealed in the MIC
measurement (Table 3.2). Next, we introduced the D408A mutation into both constructs to
examine the effect of this additional mutation on the formation of disulfide bond linked
AcrA-AcrB complex. If the D408A mutation had a significant impact on the interaction
between AcrB and AcrA, we expect to see a reduction of the intensity of the high molecular
weight AcrA-AcrB complex. As shown in Figure 3.1c, disulfide bond formation was to a
similar level in both constructs, suggesting that the additional D408A mutation did not
have a significant impact on AcrA-AcrB interaction.
To examine if the additional expression of AcrA from the same plasmid as the
AcrB-D408A have any impact on the competition with the genomic AcrB, we introduced
plasmid pBAD33-AcrAB-D408A into the wild type BW25113 strain and examined the
MIC. Both AcrA and AcrB-D408A expressed at levels much higher than their genomic
counterparts (Figure 3.1d), and yet, no dominant negative effect was observed (Table 3.3).
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Figure 3.1 Characterization of mutants defective in the proton translocation pathway.
a) The point mutation did not affect expression level. Anti-AcrB Western blot analysis of
the expression of all five mutants and the wild-type AcrB from plasmid transformed into
BW25113. Sample prepared from plasmid-free BW25113 (\) was also prepared and loaded
to serve as a control to highlight the difference in expression levels. (b) Anti-AcrB and
Anti-AcrA Western blot analyses revealing the formation of disulfide bonded AcrA-AcrB
complexes, which was reduced after incubation with BME. AcrA-P57C/AcrB-N191C
(lane 1 and 3), AcrA-T217C/AcrB-S258C (lane 2 and 4). (c) Similar to b, with the
additional D408A mutation introduced into the constructs. AcrA-P57C/AcrBN191C/AcrB-D408A (lane 1 and 3), AcrA-T217C/AcrB-S258C/AcrB-D408A (lane 2 and
4). Molecular weight markers are labeled as “M” and the molecular weight of bands (kD)
were indicated on the right. The expected bands for AcrA, AcrB, and disulfide bond linked
AcrA-AcrB are marked on the left of the gels as A, B, and AB, respectively. (d) Anti-AcrB
(left) and anti-AcrA (right) Western blot analysis of BW25113 expressing plasmid
pBAD33-AcrAB (WT) or pBAD33-AcrAB-D408A (D408A). Samples prepared from
BW25113 not containing plasmid was used as the control (/). For anti-AcrA Western blot,
plasmid-containing samples were diluted 4-fold before being loaded into the gel.
56

Table 3.3 MIC values (µg/mL) of BW25113 and BW25113∆acrAB strains containing the
indicated plasmid encoding gene for both AcrA and AcrB.
Substrate

NOV

ERY

TPP

EtBr

R6G

/

4

4

8

4

16

WT

32

32

128

128

32

AcrA/AcrB-D408A

4

2

8

8

8

AcrAP57C/AcrBN191C

32

16

64

64

32

AcrA-T217C/AcrB-S258C

64

16

128

128

32

/

256

32

1024

512

512

AcrAB-WT

256

64

1024

512

1024

AcrAB-D408A

256

32

1024

512

512

BW25113∆acrAB containing

BW25113 containing

3.3.2 AcrB Mutants Defective in Substrate Binding
One feature of the AcrAB-TolC complex that has drawn much research interest is
their ability to efflux a large array of substrates ranging broadly in molecular weight,
charge, and hydrophobicity. Many mutations have been introduced in the substrate binding
pocket in AcrB to probe their impact on the efflux of different substrates 55, 100. We chose
three such mutants to include in this study, F610A, I278A, and F178A, since they were
reported to have the most significant impact on efflux. First, plasmids containing single
residue mutations at these sites were introduced into BW25113∆acrB to examine their
activities (Table 3.3). While the F610A mutant is largely inactive, both F178A and I278A
remained partially active, which is consistent with previous reports

163

. It is clear that in

general, single point mutations introduced at the substrate binding site are not as
detrimental as mutations introduced in the proton translocation pathway. This is reasonable
when considering several residues collectively form a substrate binding site, while the
proton translocation pathway is more linear.
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Next, plasmids encoding these mutations were transformed into BW25113 to determine
their impact on efflux activity. Similar to proton relay pathway mutants, the MIC values of
the strain were not significantly affected (Table 3.4). The presence of AcrB mutants
defective in substrate binding does not display the dominant negative phenotype either.
Table 3.4 MIC values (µg/mL) of BW25113 and BW25113∆acrB strains containing the
indicated plasmid encoding AcrB mutants defective in substrate binding.
Substrate

NOV

ERY

TPP

EtBr

R6G

NA

/

4

4

4

8

8

1

WT

128

64

256

128

256

4

F610A

8

8

64

32

128

ND

F178A

64

8

128

128

256

ND

I278A

32

32

128

128

128

ND

/

256

64

1024

512

1024

4

WT

512

128

1024

512

1024

4

F610A

512

64

1024

512

1024

2

F178A

512

64

1024

512

1024

4

I278A

512

64

1024

512

1024

4

BW25113∆acrB
containing

BW25113 containing

Next, we examined the expression of these mutants under the basal condition
(Figure 3.2a). Similar as described above, the plasmid-encoded mutants were expressed at
a much higher level compared to the level of the genomic AcrB, indicating that the lack of
impact on MIC is not due to the lack of expression.
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To determine if a mutation in the substrate binding pocket of AcrB (F610A) affects
interaction between AcrB and AcrA, we used the disulfide bond pairs as described above
and introduced an additional AcrB F610A mutation (Figure 3.2b). Similar as in Figure
3.1b, AcrA-AcrB complexes were observed, similar as in samples without the F610A
mutation, suggesting that the AcrB F610A mutant still binds with AcrA.

Figure 3.2 Characterization of AcrB mutants defective in substrate binding.
(a) The point mutation did not affect expression level. Anti-AcrB Western blot analysis of
basal expression of all three mutants and the wild type AcrB from plasmid transformed
into BW25113. Sample prepared from plasmid-free BW25113 (\) was also prepared and
loaded to serve as a control to highlight the difference in expression levels. (b) Anti-AcrB
and Anti-AcrA Western blot analyses revealing the formation of disulfide bonded AcrAAcrB complexes, which was reduced after incubation with BME. AcrA-P57C/AcrBN191C, F610A is in lane 1 and 3, and AcrA-T217C/AcrB-S258C, F610A in lane 2 and 4.
Molecular weight markers are labeled as “M” and the molecular weight of bands (kD) were
indicated on the right. The expected bands for AcrA, AcrB, and disulfide bond linked
AcrA-AcrB are marked on the left of the gels as A, B, and AB, respectively.
3.3.3 Slow Dissociation of the AcrAB Complex
We speculate that the AcrAB complex, once formed, dissociates very slowly. To
experimentally test this speculation, we introduced a plasmid encoding AcrA bearing a
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histag at the C-terminus (AcrA-his) into a wild-type and the corresponding acrA knockout
strains. We first confirmed that under our experimental condition, the genomic AcrB could
not be purified using metal affinity chromatography (Figure 3.3a). In the absence of the
plasmid, no AcrB could be detected in the eluate in anti-AcrB Western blot. In contrast,
when AcrA-his was introduced into the cells, AcrB could be detected in the eluates,
indicating that it was co-purified through interaction with AcrA-his. Interestingly, the AcrB
band intensity was higher in the eluate prepared from the acrA knockout strain, indicating
more AcrB were co-purified. Next, we examined the time course of co-purification. The
rationale is, in the wild-type strain, genomic AcrB and AcrA form stable complexes. If the
dissociation is fast, the introduced AcrA-his will quickly compete with genomic AcrA to
form a complex with AcrB, and in turn enable purification of AcrB through metal affinity
chromatography. Otherwise, if the dissociation is slow, then it takes much longer for the
competition to happen. We monitored the formation of AcrAB complex between the
genomic AcrB and plasmid-expressed AcrA-his at three-time points, right after the
induction period, and 5 and 17 h after induction (Figure 3.3 b). We performed crosslinking
right before protein extraction and purification to stabilize the complexes. As a control
experiment, we also examined the formation of the AcrAB complex between the genomic
AcrB and plasmid-expressed AcrA-his in an acrA gene knock-out strain. In this case, we
do not expect competition from the genomic AcrA; thus complex should form faster. We
found that the formation of the complex is plateaued much faster in the acrA knockout
strain, as intensities of the eluates prepared from 5 and 17 h into incubation were very
similar. In contrast, it took much longer for AcrB to interact with AcrA-his in the wild type
strain, which is likely due to the requirement of an extra step of AcrAB dissociation
between the genomic AcrA and AcrB.
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Figure 3.3 Co-purification of genomic AcrB with AcrA-his.
(a) Anti-AcrB Western blot analyses of samples prepared from BW25113 or
BW25113ΔacrA with or without plasmid-encoded AcrA-his. (b) Anti-AcrB Western blot
analyses of samples collected after 0, 5, or 17 h of incubation following the induction of
AcrA-his production in BW25113 or BW25113ΔacrA strains. Dithiobis-(succinimidyl
proprionate) (DSP) crosslinking was performed to stabilize the AcrAB complex before
protein purification. Reduction using dithiothreitol (DTT) breaks the disulfide bond in the
linker of DSP and the complex into AcrA and AcrB subunits. Molecular weight markers
are labeled as “M”, and the molecular weight of bands (kD) were indicated on the right.
The expected bands for AcrB and DSP linked AcrA-AcrB are marked on the left of the
gels as B and AB, respectively.
3.4

Discussion

The dominant negative effect describes the situation in which the phenotype is dominated
by the negative impact of the functionless mutant. The observation of the dominant
negative effect has been used in many studies to investigate the mechanism of protein–
protein interaction, including the identification of protein–protein interactions interface 164,
determination of enzymatic activity related to oligomerization
mutations in genetic disorders 166, 167.
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165

, and the effect of

In the process of AcrAB-TolC assembly, there are many steps where the incorporation of
a functionless AcrA or AcrB mutant would negatively impact the efflux activity. First, all
three proteins in the system are oligomers. AcrB and TolC are obligate timers, while AcrA
is believed to exist as a dimer or trimer in the free form and assembles into a hexamer in
the pump complex

59, 168

. While AcrA and AcrB are believed to form a complex in the

absence of substrate and efflux, TolC assembles with AcrAB during active efflux. When a
functionless AcrB mutant is expressed in excess in a wild type E. coli cell containing
genomic AcrB, we expect them to compete with their genomic counterpart to engage
genomic AcrA, forming non-functional interactions to reduce the overall efflux activity. In
addition, we expect the competition for genomic TolC will further enhance the dominant
negative effect. For this competition to occur, we chose mutants that are defective due to
mechanisms not directly related to the interaction between AcrA and AcrB. The structure
of the AcrAB-TolC complex and location of mutants mentioned in this study are shown in
Figure 3.4.
We determined the expression level of the mutants relative to their genomic
counterpart. Using serial dilution and quantitative Western blot analysis, we found that the
expression levels of the AcrB mutants were 10–20 folds of the level of the genomic AcrB.
With this high level of excess, we expect to observe a strong dominant-negative effect if
the mutants were actively involved in the pump assembly, competing for binding partners.
We constructed two groups of AcrB mutants, defective in different aspects. We observed
that the effect of certain mutations was not always the same for different substrates. For
example, T978A mutation in AcrB is detrimental to all substrates tested except for R6G,
while F178A mutation in AcrB drastically reduced the MIC for ERY, but not as much for
other substrates tested. This difference in mutation effects has been observed in many
studies characterizing AcrA and AcrB mutants, for example, 62, 100, 169. We speculate that
this difference could be due to differences in the binding and interaction of specific
substrates with the pump complex. The substrates vary drastically in their size, shape,
structure, and charged state. As a result, the subgroup of residues that they interact with on
their way to be transported are not likely to completely overlap. Therefore, point mutations
introduced in AcrA and AcrB could have different impacts on specific substrates.
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Figure 3.4 Structure of the AcrAB-TolC complex with the residues mutated in this study
highlighted in AcrB structure.
AcrB mutations are labelled as; B1-F178A, B2-I278A, B3-D407A, B4-D408A, B5F610A, B6-K940A, B7-R971A, B8-T978A. AcrAB crystal structure is created using
pymol from 5N5G.pdb (https://pymol.org/2/)
Mutants defective in the proton translocation pathway still form trimers
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and

interact properly with AcrA (Figure 3.1c). Then, was why no dominant negative effect
observed? One possibility is that the genomic AcrA and AcrB are transcribed together,
sharing the same mRNA. Hence, the newly produced AcrA and AcrB could be clustered
as well. As a result, the genomic AcrA and AcrB form a AcrAB complex as soon as they
are translated and inserted into the membrane (AcrB) or secreted into the periplasm with
lipid anchoring (AcrA). Since the local concentration of the genomic proteins are high,
they associate with each other with a much higher chance than associate with a plasmidencoded partner. Another requirement for the observed activity is that the AcrAB complex,
once formed, should be resistant to dissociation. Otherwise, the high concentration of AcrB
mutant in the cell membrane would be effective in competing with genomic AcrB to form
a nonfunctional AcrAB complex.
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CHAPTER 4. Study of multi-drug efflux system protein degradation
in E.coli using transposons library
4.1

Introduction
The pathogens have evolved different mechanisms for their survival. The antibiotic

resistance in the pathogens is one such significant evolvement. Moreover, some pathogens
have acquired the mechanisms to resist multiple drugs. These have created problems in the
treatment of infectious diseases. There are several major mechanisms from which microbes
develop drug resistance, including i) genetic mutation or enzymatic alteration ii)
inactivation of drugs by enzymatic degradation, iii) antibiotic modification, iv) Loss of
porin and changes in membrane permeability, v) alteration of the drug target, and vi)
overexpression of efflux pumps17, 170. Our research work is mainly focused on studying a
multidrug resistance mechanism known as active efflux. Our primary focus is on the
Resistance-Nodulation-Division (RND) superfamily member AcrAB-TolC efflux pumps
in E. coli. AcrAB-TolC forms a tripartite complex that spans the inner membrane,
periplasmic space, and outer membrane of E. coli

137

. The pump assembles by inner

membrane AcrB associating with periplasmic protein AcrA, and outer membrane channel
TolC44,

46, 171

. Inner membrane transporter AcrB plays a pivotal role in substrate

recognition, binding, and translocation to the exit channel70, 172. Hence, the researchers
focus on identifying methods to disrupt the AcrB either by targeting substrate binding sites,
inhibiting pump assembly, or protein degradation methods113, 157. This chapter focuses on
the identification of novel protease mechanisms important in AcrB degradation.
Protein degradation in both prokaryotes and eukaryotes require energy input,
typically by hydrolysis of ATP. In prokaryotes, the proteins are degraded by an ATPdependent pathway involving proteases including ClpAP, ClpXP, FtsH, and Lon104, 112, 173.
Two well-studied examples are AAA+ proteases ClpAP and ClpXP. Protein degradation
by ClpXP and ClpAP is initiated by recognizing the specific protein for degradation105.
Signals for degradation include the C terminal tagging of the protein by the ssrA tag or Nterminal tagging via the N-rule pathway108, 174.
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In an effort to study the lifetime of AcrB in E. coli cells, Chai et al., discovered that
the introduction of a small peptide tag, the small stable RNA A (ssrA) tag introduced at
the C terminus of AcrB facilitates complete degradation of AcrB113. The ssrA is a 11 amino
acid residue tag (Amino Acid sequence-AANDENYALAA). The natural function of ssrA
is to rescue the stalled ribosomes on truncated mRNA lacking the stop codon110, 175. The
ssrA tag is added to the C-terminus of the incompletely synthesized proteins during
translation. ClpP, ClpX, and a chaperon SspB have been identified to be involved in the
degradation of ssrA tagged AcrB. However, partial degradation was observed when these
genes were disrupted, indicating that other players were likely involved in the process113.
The goal of the study described in this chapter is to discover novel proteases and
protein degradation mechanisms that are involved in the destruction of AcrB. Specifically
for this purpose, the transposons library has been created, which contains an extensive
collection of strains with random gene knockouts. Transposable elements are generally
known as "jumping genes/selfish genes." These DNA sequences move from one location
to another in the genome118, 126. The identification of transposons has led to significant
discoveries in various scientific aspects116, 118. The main problem associated with genome
studies in sequencing large DNA segments is sequencing an insert within the interior of a
DNA. Alternative techniques have been developed, such as genome walking/ primer
walking and shotgun subcloning, to overcome these restrictions118. The Tn5 transposons
system, which has the cut and pastes mechanism, has been widely used in different
studies120, 129. Transposons library creations have facilitated the identification of genes
involved in virulence and other non-essential processes125. Furthermore, to get insight into
the essential gene, gene function, and genetic linkages, sophisticated deep DNA
sequencing approaches have been influential in the use of transposon libraries. The Tn5
transposons system have been used in our study, which comes under the group of
composite transposons121
Comparatively, an E.coli strain containing AcrB-WT has a higher tolerance to
antibiotics than a strain containing AcrB-ssrA. Hence, in this study, the first goal was to
establish a screening strategy to identify antibiotic concentrations under which strain
containing AcrB-WT would grow but not those containing AcrB-ssrA. Next, plasmid
encoding AcrB-ssrA was used to introduce the transposons using the Ez-Tn5 <Kan>
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transposome system. The transposon has a kanamycin resistance marker, allowing mutants
to be selected when the transposon is inserted into the recipient strain's genome. Insertion
of the transposon is random, and thus we speculate there is an opportunity for it to disrupt
genes important for the degradation of AcrB-ssrA. In this case, the expression level of
AcrB-ssrA would be higher in the strain, and thus lead to higher tolerance of antibiotics
that are substrates of AcrB. The elevated level of AcrB-ssrA expression was then
confirmed using anti-AcrB antibody and Minimum inhibitory concentration assays. PCRbased sequencing methods and finally, the next-generation sequencing method (NGS) was
used to determine the transposons inserted gene location. Data analyses revealed the clpX
gene was disrupted in the strains with elevated levels of AcrB-ssrA expression.

4.2

Material and Methods

4.2.1 Knockout strain creation, competent cell preparation and Transformation
BW25113 wild-type strain was obtained from Yale E. coli genetic resources.
BW25113∆acrB was produced in the lab using the E. coli gene deletion kit (Cat #K006,
Gene Bridge). The same kit was used to remove the kanamycin cassette to obtain the cells
without kanamycin resistance (BW25113∆acrB; K-). Next, to incorporate the ssrA into the
system, competent cell preparation was done, followed by the transformation. E. coli
BW25113∆acrB; K- were transformed with the pQE70 AcrB -ssrA (ampicillin resistanceAmp+) plasmid and plated on Luria broth (LB)-Amp+ plate following the incubation at
37°C overnight. Furthermore, pQE70 AcrB WT was transformed into E. coli
BW25113∆acrB; K- and BW25113 WT cells; pQE70 AcrB WT and pQE70 AcrB ssrA
into BW25113∆clpX cells. These were later used in minimum inhibitory concentration
(MIC) assay.
Preparation of BW25113∆acrB; K- pQE70 AcrB- ssrA competent cells: A single
colony was picked from the LB-Amp+ plate and used to inoculate 5 mL of fresh LB
containing ampicillin (100 mg/mL; 1:1000 dilution). The culture was incubated at 37°C
overnight. The next day 100 mL of liquid LB medium containing ampicillin was inoculated
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using 500 µL of the overnight culture. The new culture was incubated at 37°C until its
OD600 reached 0.5, which was used for the electrocompetent cell preparation. The culture
was kept on ice for ~ 20 mins and then centrifuged at 2400rpm for 20 mins at 4°C followed
by resuspension with ice-cold sterile distilled water (100 mL). Next, it was centrifuged at
2400rpm for 20 mins at 4°C. The washing step with ddH2O was repeated. Then the cell
pellets were resuspended in 10% ice-cold glycerol (40 mL) and centrifuged at the same
conditions. The glycerol wash step was repeated one more time, and the supernatant was
removed. The pellet was resuspended in 0.2mL of 10% glycerol.
The prepared BW25113∆acrB; K- pQE70 AcrB -ssrA electrocompetent cells
(Amp+) were used for the transposomes insertion and MIC assays described in the below
sections.
4.2.2 The Minimum Inhibitory Concentration (MIC) LB agar plate assay and liquid
assays to compare the growth of different E. coli strains.
The first step in creating the transposons library is to identify a reliable screening
method to use after the insertion of transposomes. For our purpose, we need to identify a
condition in which the BW25113∆acrB containing pQE70 AcrB ssrA cells do not grow,
while the BW25113∆acrB containing pQE70 AcrB WT cells grow. The BW25113∆acrB
pQE70 AcrB WT strain, containing a higher level of AcrB, should be more tolerant to
AcrB substrate than BW25113∆acrB pQE70 AcrB ssrA, in which the expression of AcrBssrA was significantly reduced. The condition in which only the BW25113∆acrB pQE70
AcrB WT strain, but not the BW25113∆acrB pQE70 AcrB- ssrA strain grows, will be used
to screen for new mutants that have gene disruptions that lead to functional loss of other
proteins that are involved in AcrB-ssrA degradation. We expect to rediscover ClpX, ClpP,
and SspB in our screening, which will serve as a positive control for the effectiveness of
our screening method. In addition, we are looking for novel genes where the disruption
will also lead to the survival of the strain. The following MIC assays were performed to
find conditions of efficient screening assay. Two known AcrB substrates were tested,
erythromycin (ERY), and novobiocin Sodium (NOV).
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The LB agar plates with different antibiotic concentrations ranging from 100-20
µg/mL for novobiocin and erythromycin were prepared. To each plate 15 µg/mL of
kanamycin was added as the second substrate. 5mL cultures at OD 0.5 was used for the
experiment. We expect the concentration in the culture is 5x108 per mL. A dilution series
was prepared from 109 to 104. After establishing a screening method, the next step was to
create a random insertion library using a transposome system.
Liquid MIC assay was performed for the BW25113 ∆acrB pQE70 AcrB WT,
BW25113 ∆acrB pQE70 AcrB ssrA, BW25113 pQE70 AcrB WT, BW25113 pQE70 AcrB
ssrA, BW25113 ∆clpX pQE70 AcrB WT and BW25113 ∆clpX pQE70 AcrB ssrA strains
using NOV and ERY.
4.2.3 Electroporation of BW25113 ∆acrB pQE70 AcrB ssrA electrocompetent cells
with EZ-Tn5 <KAN-2>Tnp transposome and selection of transposed clones
The insertion of transposons to create the random mutations was achieved using the
Lucigen Ez-Tn5TM <Kan-2> Tnp TransposomeTM kit (Cat # TSM99K2). The transposons
insertion was done by electroporation of the BW25113 ∆acrB pQE70 AcrB ssrA
electrocompetent cells (Amp+) with one microliter EZ-Tn5 <KAN-2>Tnp Transposome.
Electroporated at 2200 V, using a 2 mm cuvette, for ~5.7 ms using Eppendorf Eporator®,
(Catalog #4309000019). The electroporated cells was immediately recovered after
electroporation using Super Optimal broth with Catabolite repression (SOC) medium;
(0.5% Yeast Extract, 2% Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM
MgSO4, 20 mM Glucose). SOC medium was added to the electroporation cuvette to 1 mL
final volume immediately after electroporation. The medium was pipetted gently to mix
and then incubate on a 37°C shaker for 60 minutes to facilitate cell outgrowth (Figure 4.1)
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Figure 4.1 The schematic representation of the transposons library creation using
electroporation method.
The image is belongs to Lucigen Inc. (https://www.lucigen.com/docs/slide-decks/LucigenEZ-Tn5-Transposon-Tools.pdf)
The control experiment was conducted using pET28a sfGFP plasmid (Kan+)
electroporated in to the BW25113 ∆acrB pQE70 AcrB ssrA electrocompetent cells
(Amp+). Then 100 μL aliquots of the recovered cells were plated on plates containing 50
μg/mL and 15 μg/mL kanamycin- for control and experimental samples, respectively. The
transposome inserted sample was plated on kanamycin (15 μg/mL) included different
antibiotic plates; NOV- 20 μg/mL, 40 μg/mL and ERY 20, 40 μg/mL. All the plates were
incubated at 37°C incubators overnight (~16hrs). The rest of the recovered cultures were
stored at 4°C. The next day, the plates were checked for colonies. Next, colonies were
chosen from each plate and used to inoculate 3 mL cultures overnight; simultaneously,
each colony chosen was streaked on a new plate, and a number was assigned for each
colony. MIC assay was performed for the obtained colonies using NOV and ERY
substrates.
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4.2.4 Inhibition by Phenylalanine-Arginine-β-naphthylamide dihydrochloride
(PAβN) Efflux pump inhibitor to confirm the elevation of MIC is due to
AcrB activity
To confirm the observed effect on MIC depends on the AcrB expression, the efflux
pump inhibitor PAβN (MCE; Cat# HY-101444A) was used to inhibit AcrB-mediated
efflux using samples that have been selected from the previous MIC assays with ERY.
The antibiotic concentration for erythromycin was decided based on the previous
MIC results. The assay with inhibitor was optimized by using a concentration range of
PAβN (10, 20, 30, 40, and 50 µg/mL) with 1 mM Mg2+. Magnesium was used to avoid the
outer membrane disruption that can be caused by the high concentration of inhibitor. From
the screening, 50 µg/mL of inhibitor was selected and used for the MIC assay. After
overnight (~16 hrs) incubation, the plate reading was taken using the plate reader at OD
600 nm. The sample number finalized through this inhibitor assay, and the second phase
of the MIC assay proceeded for the western blot analysis, genomic DNA extraction, and
sequencing.
4.2.5 FLAG tag insertion, Western Blot analysis with Anti AcrB CT and FLAG
antibody
The selected samples were used to prepare 5 mL overnight LB cultures. The next
day these cultures were centrifuged to obtain the cell pellet.

The cell pellet was

resuspended in 50 µl of the lysis buffer (PBS (pH 7.5), 2.5 mM MgCl2, 0.5mM CaCl2, 10
µM DNase (Final pH 7.6) and 50 µl SDS loading dye (Tris-HCl, pH 6.8, 6%SDS, 48%
glycerol, 0.03% bromophenol blue, 9% 2-Mercaptoethanol). The samples were incubated
at 37oC for 30 mins, centrifuged at max speed (150,000 rpm) for 1 minute, and the
supernatant was subjected to the SDS PAGE analysis. The SDS-PAGE electrophoresis was
done at 220 V for 40 mins using 15% SDS gel. Then the gel was transferred to a
Polyvinylidene difluoride (PVDF) membrane stack between the blotting papers. The
transfer was done at 380 V for 25 mins, and then blot was proceeded for the western blot
analysis. Briefly, the PVDF membrane was incubated in the blocking solution (5% skim
milk powder+ Tris Buffered Saline (TBS) buffer; Tris-HCl, NaCl pH 8.0) for 1 hr. at room
temperature on a shaker. Then the membrane was transferred to Anti AcrB CT (Rabbit)
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antibody (1:5000 antibody in TBS buffer). The membrane was incubated for 1.5 hrs at
room temperature. The membrane wash was performed using wash buffer (TBS + 1:1000
tween 20) 3 times, 10 mins each time. Then the membrane was transferred to a TBS buffer
containing the Anti Goat to Rabbit secondary antibody (1:5000 in TBS buffer). The blot
was Incubated for 45 mins with the antibody, followed by washing as described above.
Then the BCIP/NBT (5-bromo-4-chloro-3'-indolyphosphate and nitro-blue tetrazolium)
solution was used for staining the membranes and shake until the color is developed.
Another plasmid construct was created in which the FLAG tag was inserted at the
N terminus of the pQE70 AcrB-WT and pQE70 AcrB-ssrA plasmids using the fast cloning
method156. The BW25113 ∆acrB pQE70 FLAG AcrB WT and BW25113 ∆acrB pQE70
FLAG AcrB ssrA used for the Western blot analysis with anti- FLAG antibody. The same
procedure was followed with Anti FLAG antibody (Santa Cruz Biotechnology).
4.2.6 Genomic DNA extraction and sequencing
Genomic DNA was extracted from colonies that show promising results from the
MIC assay and processed for sequencing to identify the candidate genes. As the first step,
1.5 mL of overnight cultures were prepared from colonies identified through MIC assays.
The PureLink™ Genomic DNA Mini Kit (Cat#:K182001, Thermofisher) was used in
genomic DNA extraction. Briefly, the method is as follows:
The cells were harvested at 9000 rpm for 5 mins. Then those were proceeded to
prepare the lysate using Pure link genomic Kit. First, 180 µl of the digestion buffer +20 µl
of Proteinase K was added, vortexed briefly, and incubated at 55oC for 1 hr. with occasional
vortexing (5s vortex). Then 20 µl of RNase was added, vortexed, and incubated at room
temperature for 2 mins. After that, 200 µl of lysis buffer+200 µl of 99.5% Ethanol was
added, followed by vortexing and mixing of samples. Next, the lysate was transferred to
the spin column and centrifuged at 9,000 rpm for 1 min at room temperature. The next step
was washing. First 1,500 µl wash buffer was added and centrifuged at 9000 rpm for1min,
next 500 µl wash buffer was added and centrifuged at 15,000 rpm for 3 mins. Genomic
DNA was eluted by adding 30 µl of elution buffer, incubating for 1 min at room
temperature, and centrifuging at 15,000 rpm for 1 min. The elution step was repeated using
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another collection tube with 30 µl of elution buffer. Agarose gel electrophoresis was
performed to check the presence of DNA. Furthermore, a survey scan was done at
wavelengths 260 nm and 280 nm to check the DNA quality.
4.2.7 Sequencing results analysis and identified gene verification
The samples were pooled and sent for Nest Generation Sequencing (NGS) (in
collaboration with China). The extracted genomic DNA was sequenced using long-read
MinION (Oxford Nanopore) and short-read Illumina MiSeq technologies. The long reads
were generated by Oxford Nanopore MinION flowcell R9.4 with a depth more than 300
times and the 150 bp paired-end short reads were generated by Illumina MiSeq system
(Illumina, San Diego, CA, United States) with a depth more than 100 times. The MinION
reads were filtered using Filtlong (version 0.2.0) to remove any reads < 2000 bp, followed
by removing the lowest 10% of reads by quality. Complete sequence assembly was
performed with Canu version 1.5 using a combination of short and long reads, followed by
error correction by Pilon version 1.12.
The sequences for each sample were used in the NCBI; nucleotide to nucleotide
Blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The sequence was entered in the FASTA
format, and the reference sequence accession number for Escherichia coli str. K-12 substr.
MG1655, complete genome Escherichia coli str. K-12 substr. MG16554,641,652 bp
genomic sequence was given as U00096.3. As shown in the following image either the
highly similar or somewhat similar sequence options were selected and performed the blast
(Figure 4.2).
The gene sequence was checked using the ClustalX2 software to match up the
regions aligning in the sample sequence and candidate gene sequence for further
confirmation. This process was followed for all the samples to find out the disrupted genes.
First, the verification of the kanamycin gene in the identified gene location was performed
using primers to amplify the Kanamycin cassette. Next, further analyses were done to
determine any other possible genes disrupted by Tn5 transposons insertion. The primers
used for this process mentioned in Table 4.1
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Figure 4.2 The figure illustrates the query and subject sequences entering and the
parameters used for BLAST

Table 4.1 Primers used for the verification process
Primer

Primer sequence 5’-3’

KAN-verification-F:

AACACGTAGAAAGCCAGTCCG

KAN-verification-R:

CCCCTGATGCTCTTCGTCCA

Tn5-clpX-verification-F：

CGATTCGATTCTGACCCATC

Tn5-clpX-verification-R：

CGTCAGTATATGGGGATGTTTC

Clpp verification-F

ATGTCATACAGCGGCGAAC

Clpp verification-R

CAATTACGATGGGTCAGAATCG

SspB verification-F：

ATGGATTTGTCACAGCTAACAC

SspB verification-R：

TTACTTCACAACGCGTAATGC
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4.3

Results and Discussion

4.3.1 Minimum inhibitory concentrations for pQE70 AcrB-ssrA and pQE70 AcrB
WT strains in BW25113 ∆acrB
The identification of a proper condition is essential for the establishment of an
efficient screening assay. As for the first step, we performed the MIC assay. This technique
is used to determine the lowest concentration of an antibiotic that inhibits the growth of a
bacteria. MIC assay is an easy method that can be done on a small scale. This assay can be
performed either in a liquid medium or solid medium. However, the most prominent
process is the liquid assay. During MIC measurement, serial dilutions of different
antibiotics are added to the growth medium. In this experiment, we used two different
antibiotics for liquid assay and solid assay. Table 4.2 summarizes the MIC values for each
of the strains for different antibiotics for liquid assay. Figure 4.2 shows the differential
growth of the wild type (WT) and ssrA strain to varying concentrations of novobiocin and
erythromycin. During the actual screening, cells are be plated onto agar plates (solid assay).
The liquid assay is used here to identify the proper concentration range. The rationale is
that differences in protein expression level (AcrB-ssrA is less than WT AcrB) will lead to
a smaller MIC for the strain containing AcrB-ssrA. Once we have identified a suitable
substrate and a concentration, we will be able to select mutants containing gene deletions,
enhancing the expression level of AcrB-ssrA. Thus, this gene/s is likely to be involved in
the degradation of AcrB-ssrA.
Erythromycin is a macrolide antibiotic that participates in the inhibition of protein
synthesis by binding to the 50S subunit of the ribosome during translation in bacteria.
Novobiocin is an aminocoumarin that binds to DNA gyrase and acts as a competitive
inhibitor of ATPase activity. A two-fold or four-fold difference in MIC values has been
observed for strains containing either the WT or the ssrA tagged constructs. Thus, these
two substrates could be used in the screening. The LB agar assay results facilitate
identifying the proper concentration for the establishment of transposons library screening.
As shown in Figure 4.2, at very low concentrations a (10 µg/mL) and very high
concentrations d (100 µg/mL), the difference between WT and ssrA is insignificant.
However, under conditions b (20 µg/mL) and c (40 µg/mL). a detectable difference could
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be observed between the two samples. Therefore, those are suitable conditions for
screening.
Table 4.2 The MIC values for pQE70 AcrB-ssrA and pQE70 AcrB WT strains in BW25113
∆acrB, WT and ∆clpX
NOV

ERY

pQE70 AcrB WT

320

160

pQE70 AcrB ssrA

80

40

pQE70 AcrB WT

640

320

pQE70 AcrB ssrA

160

80

pQE70 AcrB WT

640

320

pQE70 AcrB ssrA

160

80

BW25113 ∆acrB containing

BW25113 containing

BW25113 ∆clpX
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Figure 4.3 A representation of the streaking pattern on the LB agar plate used for the solid
assay.
The dilution series ranges from 109 to 104. The top half of the plate was spotted using the
WT strain, and the bottom half of the plate was spotted with ssrA strain. (the bottom should
be labeled similarly as the top) B) This image shows the results obtained in a solid assay
using NOV and ERY. All the plates contain 15 µg/mL concentration of kanamycin.
Concentrations of NOV or ERY in each panel as; a) 10 µg/mL b) 20 µg/mL c) 40 µg/mL
d) 100 µg/mL
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4.3.2 The Ez-Tn5 transposons insertion by electroporation
The random insertion of the transposons was performed using the electroporation
method. Figure 4.4 displays the colony growth of the control and the experimental strains
with different concentrations of the antibiotics. In these experiments, different antibiotic
concentrations were fine-tuned. The kanamycin 50 µg/mL control plate has many colonies;
the pET28a sf-GFP control is intrinsically kanamycin-resistant (Figure 4.4 A). This result
demonstrated that the electroporation transformation was successful. BW25113 ∆acrB
pQE70-AcrB-ssrA with transposome insertion on kanamycin 15 µg/mL plate also has a
higher number of colonies (Figure 4.4 B). The BW25113 ∆acrB pQE70-AcrB-ssrA cells
do not have intrinsic resistance to kanamycin. Hence, this reveals transposons insertion is
successful.
Plates containing LB-agar with different NOV, ERY concentrations, and
kanamycin (15 µg/mL) allow for the selection of colonies with an expression similar to
AcrB-WT. Because, under these low NOV or ERY concentrations, the BW25113 ∆acrB
pQE70-AcrB-ssrA strain does not show significant growth. The growth at these
concentrations will show that there might be a mutation of the genome of the strain
containing AcrB-ssrA that increased its expression level (and thus drug tolerance) (Figure
4.4 C, D, E).
The colonies picked from these plates were subjected to further liquid MIC assays
to confirm that they grow at higher antibiotic concentrations. The same two substrates were
used for the liquid assay (Table 4.3). The samples show similar or higher MIC values than
the WT strain, implying that the AcrB expression has increased despite ssrA. Hence, there
could be a disruption in a gene responsible for the AcrB degradation.
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Figure 4.4 The colony growth of the experimental and control strains with transposome
insertion plated in
(A) control pET28a sf-GFP in kanamycin 50 µg/mL (B) BW25113 ∆acrB pQE70-AcrBssrA with transposome insertion plated in kanamycin 15 µg/mL. (C), (D), (E) BW25113
∆acrB pQE70-AcrB-ssrA with transposome insertion plated in Erythromycin 20 µg/mL+
kanamycin 15 µg/mL, Novobiocin 40 µg/mL+ kanamycin 15 µg/mL, Erythromycin 40
µg/mL+ kanamycin 15 µg/mL respectively. Red circle highlights the location of colonies.
C

D

E

Table 4.3 The MIC values for samples picked from the transposons library
Sample

ERY

NOV

S1

320

80

S2

160

320

S3

320

320

S4

320

320

S5

320

320

S6

320

320
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Table 4.3 (Continued)
S7

>320

160

BW25113 ∆acrB; K-

40

40

BW25113 ∆acrB; K- pQE70 AcrB WT

160

320

4.3.3 MIC assay with Phenylalanine-Arginine-β-Naphthylamide dihydrochloride
(PAβN) Efflux pump inhibitor
Several inhibitors have been identified for RND family efflux pumps. These
inhibitors increase antibiotics efficacy, reduce the pathogen's resistance occurrence, and
reduce the pathogen's infection ability.Among available Efflux Pump Inhibitors (EPI),
PAβN is a frequently studied efflux pump inhibitor. EPIs are essential in clinical use to
inhibit the multidrug resistance of bacteria. We used this inhibitor in our experiment to
confirm the increase of the MIC value for transposons inserted BW25113 ∆acrB pQE70AcrB-ssrA strain was due to the activity of the AcrAB-TolC efflux pump.
The PAβN is capable of significantly reducing the antibiotic resistance of E. coli
for selected compounds that are AcrB substrates. The combination of the antibiotics (pump
substrate) and the inhibitor facilitate the study of efflux-mediated multidrug resistance.
Under our experimental condition, we observed the inhibitor alone does not influence
bacterial growth. All the tested colonies grow normally in the presence of the inhibitor.
However, when it was added along with ERY the colonies had a four-fold decrease in MIC
values. These observations explain that the previously observed higher MIC values are due
to the efflux activity of AcrB-ssrA, likely a result of increased expression level due to a
mutation in a gene that regulates the ssrA tagged protein degradation.
Table 4.4 shows the results obtained for some of the tested strains. The highlighted
values show the growth in the examined antibiotic concentration and the strains that were
selected for further analysis. ERY and 50 µg/mL of PAβN have been used in this
experiment.
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Table 4.4 The MIC values for the selected samples in the presence of an antibiotic and with
or without inhibitors
Sample

Inhibitor PAβN (50 µg/mL)
(-)

(+)

S1

320

80

S2

160

80

S3

>320

80

S4

>320

80

S5

>320

80

S6

320

160

S7

>320

80

BW25113 ∆acrB; K-

40

40

BW25113 ∆acrB; K- pQE70 AcrB WT

160

40

4.3.4 The selected colony analysis with western blot and sequencing
The above-discussed methods were used for the selection of the colonies that shows
higher AcrB activity. We tested two vectors for AcrB-ssrA expression, pQE70 AcrB ssrA
and pQE70- AcrB WT. Furthermore, we created pQE70 FLAG -AcrB- ssrA and pQE70
FLAG -AcrB WT and used those for initial testing for AcrB expression in BW25113 ∆acrB
and BW25113 ∆clpX cells (Figure 4.5). The expression of AcrB-ssrA is significantly lower
in the wt strain compared to the BW25113 ∆clpX strain. This confirms the role of ClpX in
AcrB-ssrA degradation, as discussed in previous research.
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Figure 4.5 Western blot analysis with anti AcrB-CT and anti-FLAG antibodies.
(A)1. BW25113 ∆acrB- pQE70 AcrB WT, 2. BW25113 ∆acrB- pQE70 AcrB- ssrA, 3.
BW25113 ∆clpX- pQE70 AcrB WT and 4. BW25113 ∆clpX- pQE70 AcrB -ssrA. (B)
Western blot analysis with Anti FLAG antibody. 1. BW25113 ∆clpX- pQE70 AcrB- ssrA,
2. BW25113 ∆clpX- pQE70 AcrB WT, 3. BW25113 ∆acrB- pQE70 AcrB- ssrA, and 4.
BW25113 ∆acrB- pQE70 AcrB WT.
To determine if the AcrB expression in the selected colonies were higher, we
conducted Western blot analysis using Anti-AcrB antibody. The sample numbers are
consistent with the numbers on the MIC plates used during selection. For several samples
including 10,11,46,47,51, expression level was similar to AcrB WT (Figure 4.6).
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Figure 4.6 Western blot analysis with anti AcrB-CT antibody.
1) BW25113 ∆acrB; K-.2) BW25113 WT. 3) BW25113 ∆acrB pQE70 AcrB- ssrA. 4)
BW25113 ∆acrB pQE70 AcrB WT. Lanes 5-11 are samples 1-7 (S1-S7) respectively.
4.3.5 Genomic DNA extraction and sequence analysis.
The genomic DNA was extracted from the selected colonies using the method
described in material and methods. Then 1% agarose gel was used for the confirmation of
the presence of genomic DNA. E. coli genomic DNA is ~4.4- 5.5mb. The samples were
sent for NGS, and the received sequences were analyzed using NCBI and ClustalW
methods as described in methods.
To confirm that transpositions was successful and the selected colonies contained
the kanamycin cassette, we performed PCR to amplify the kanamycin resistance cassette
(Figure 4.7 A). The agarose gel analysis shows all seven samples have the Tn5 kanamycin
cassette. The presence of the Tn5 sequence in the clpX gene area confirms transposon
insertion. Hence, it confirmed clpX as the disrupted gene by the insertion of transposons.
A PCR was conducted to verify this insertion further. Figure 4.7 B shows the PCR products
amplify in the clpX region. Once the Tn5 is inserted, the DNA fragment should be longer
(1591 bp) than a non- disrupted clpX (1539 bp). According to the gel image, samples
3,4,5,6 migrate slowly compared to samples 1,2,7 and control (BW25113 WT). These
products were sent for sequencing, and it confirmed the presence of Tn5-clpX. The samples
1,2,7 sequencing results showed an intact clpX.
Further analysis was performed to determine which genes disruption is responsible
for the higher expression and MIC values of samples 1,2 and 7. For that purpose, we
designed primers to amplify clpP and sspB regions. These have been identified to have
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important roles in AcrB-ssrA degradation. However, the agarose gel image analysis
exhibited intact clpP and sspB regions (Figure 4.7 C).

Figure 4.7 Agarose gel electrophoresis analysis of the PCR products.
A) Confirmation of the presence of Tn5-Kanamycin cassette. B) Confirmation of clpX-Tn5
insertion. Sample 3,4,5,6 has slow migration. C) Analysis of samples 1.2 and 7. a) analysis
of sspB region b) Presence of IS4 kanamycin cassette c) Analysis of clpP region
Further analysis is required to identify the disrupted genes that increase the
expression in samples 1,2 and 7. However, due to the time and resource limitation, this
project was ended at this point.
4.4

Conclusion

Transposons library creation is one of the most versatile tools in genetic studies. It provides
efficient and robust genetic mutation analysis to identify novel genes for a particular
function, virulence genes, and non-essential genes. The availability of high throughput
sequencing methods such as NGS has made the use of transposons much more reliable and
efficient. Our purpose was to identify novel gene/genes that have an essential role in the
ssrA tagged AcrB degradation. In the long term, identifying genes important for the AcrB
degradation process would provide new pathways in studying possible inhibitors/drugs to
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reduce the drug efflux through the AcrAB-Tolc efflux pump. Even though the transposons
library formation in this experiment did not identify novel genes, it identified an already
known gene clpX. The observed increase in AcrB expression after disruption by transposon
validates the effectiveness of the strategy. Unfortunately, the size of the library created in
the current study limited the success of the search. Efficient and more reliable identification
of novel genes would require the creation of a more extensive transposons library. The
construction of a large library of mutants is crucial in transposons studies. Multiple
insertions can be detected in every possible locus in a large, complicated library. The higher
the insertion density, the more precise the identification of region-of-interest boundaries.
If the library's density is too low, certain genes may go undetected.
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CHAPTER 5. Discussion and future work
The RND family efflux pump AcrAB-TolC in E. coli and its homologs in other
Gram-negative bacteria play significant roles in conferring multidrug resistance to the
cells. The pump component structures have been investigated through crystallography and
cryo-EM methods. Even though this structural knowledge has led to the elucidation of the
substrate efflux mechanisms and pump assembly models, there are still several unanswered
questions about the AcrAB-Tolc pump system. In this study, our focus was to address three
major aspects regarding the inner membrane protein of the eﬄux complex, which is
responsible for the recognition and binding of compounds before their transportation out
of the cell. We have studied the conformational changes in functional rotation, the pump
assembly process, and AcrB-ssrA degradation.
In chapter two, we focused on understanding the dynamics of AcrB during
functional rotation in the process of drug eﬄux131. For this purpose, we introduced six
inter-subunit disulﬁde bonds into the periplasmic domain of AcrB using site-directed
mutagenesis. The goal was to study the importance of the relative ﬂexibility at the intersubunit interface. We utilized MIC, Western blot analysis, and EtBr efflux assay. The
formation of disulﬁde bond-linked AcrB oligomers, which were reduced into monomers
under reducing conditions, was analyzed through Western blot. We evaluated the impact
of mutation and formation of disulﬁde bond on eﬄux through comparison of the minimum
inhibitory concentration (MIC) of an AcrB knockout strain expressing diﬀerent mutants.
Furthermore, ethidium bromide accumulation assay was used to determine if the
reduction of activity in a double mutant is due to restriction on conformational changes by
the disulﬁde bond formation. We used dithiothreitol (DTT) as the reducing agent. In two
cases, the activities of the double Cys mutants were partially restored by DTT reduction,
conﬁrming the importance of relative movement in the respective location for function.
Nile red assay is another efflux quantification method that could have used for this study176.
To extend this study, identifying more potential disulfide bond forming locations
and studying their impact would be necessary. Ultimately, these ﬁndings provide new
insights into the dynamics of the AcrAB-TolC eﬄux pump in E. Coli
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Chapter three discussed the effect of over-expressing functionally defective pump
components in wild-type E. coli cells to probe the pump assembly process153. In this study,
we utilized the "dominant-negative" effect concept.

Based on previous studies, the

incorporation of a defective component to the pump is expected to reduce the efflux
efficiency of the complex. When considering pump components separately, mutations in
AcrB have been reported to disrupt efflux through different mechanisms. We examined
proton translocation pathway and substrate binding pathway mutants and found that none
demonstrated the expected dominant-negative effect. Our current data reveals that the
AcrAB-TolC complex assembly appears to have a proof-read mechanism that effectively
eliminated the formation of a futile pump complex. We used MIC and expression analysis
through Western blot as basic study methods. However, to investigate the efflux efficiency
of the defective pump components, incorporating Nile red assay would be beneficial.
Moreover, further studies of the pump assembly can perform regarding other elements in
the efflux pump. Thorough investigation would provide a better picture about the pump
assembly process.
The next question we wanted to answer was regarding the ArB degradation. A
previous study from our group revealed that AcrB tagged by ssrA at the C-terminus
facilitated degradation of the protein by ClpXP proteases113. In this project, we focused on
exploring other protein degradation mechanisms or proteases involve in AcrB-ssrA
degradation. For this purpose, we used transposons as the primary tool. We hypothesize
that the increased activity of AcrB-ssrA protein is due to a mutation or inactivation of a
gene involved in the degradation of AcrB-ssrA. Through gene sequence analysis, we
identified clpX as the gene location disrupted by transposons insertion. Since clpX is an
already recognized and widely studied protease system, this is not a novel finding.
However, this finding validates our transposons library creation and screening methods.
It is essential to have an extensive transposons library. It would provide more
flexibility and a wide range of gene disruptions to explore. In future work, creating a
transposons library with many mutants should be the first step in this project. One of the
significant challenges in this project was the identification of transposons inserted location.
Initially, we used several sequence analysis methods, such as Random Amplification of
Transposons Ends (RATE), arbitrary PCR method, invert PCR methods mentioned in the
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previous literature177-179. However, these methods did not provide good sequencing results,
which led us to use the next-generation sequencing (NGS) method. NGS is an expensive
method; hence, in continuing this project, one of the primary focuses should be a more
reliable, inexpensive, and effective transposons location identification method.
The following steps after identifying a specific gene include a complete analysis of
the effects of the gene. The primary focus will be on verifying the potential role of the
identified protein in membrane protein degradation, using molecular cloning, protein
expression, and purification methods. Utilizing this information to determine its structure
and potential function using available literature and genomic sequence can be the next step.
The potential function information will be helpful in experimentally testing possible
hypotheses. Moreover, investigating its role in the ssrA-facilitated degradation of other
model proteins would provide greater insight into its function.
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